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Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) 
are two chronic viral infections of humans for which no vaccine exists.  
considerable research effort has focused on in vitro, ex vivo, and animal 
models due to inherent limitations in human research. The advent of 
highly quantitative and high-throughput measurement modalities from 
increasingly small amounts of human tissue have made it possible to 
generate unprecedented amounts of information from the material 
contained within a few drops of blood. This thesis presents three novel 
methods in which blood sampling of humans with HCV or HIV has 
generated large data sets that were then analyzed using the latest 
technologies and computational methods to describe previously 
unappreciated biological features of those infections.  
This thesis explores two important aspects of HCV infection for 
which no surrogate for natural infection can be as informative: i) plasma 
microRNA signatures before, during, and after acute HCV infection using 
microRNA quantitative PCR array and ii) naturally occurring resistance 
polymorphisms in the HCV envelope to broadly neutralizing antibodies 
using a large panel of HCV pseudoparticles. This thesis also identifies 
novel restriction factors for HIV using RNA sequencing (RNAseq) 
technology to investigate naturally occurring inter-person variation in 
gene-induction in activated CD4+ T-cells of patients receiving an injection 
of pegylated interferon-alpha.  
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Background: Hepatitis C virus (HCV) and Human 
Immunodeficiency Virus-1 (HIV-1) are viruses with 
distinctly human pathogenesis. 
Viruses are small infectious entities that replicate inside living cells 
of host organisms, including single-celled hosts such as amoeba and 
bacteria. The mechanisms host organisms employ to protect them from 
pathogenic infections are likely as ancient as the existence of cellular life. 
The endosymbiotic history of mitochondria and the more recent 
observation that ~8% of the human genome is retroviral DNA have 
challenged previous notions of what defines organism, flora, and 
pathogen. The genetic ecology of life facilitates evolution in ways that we 
have only been able to appreciate recently with the widespread availability 
of genome sequencing data. These analyses have revealed duplication 
and divergence of genes with antiviral properties among mammals (1) and 
more recent emerging evidence suggests that profound selection for 
genes related to antiviral immunity have occurred geographically among 
humans (2). 
  Many viruses that are pathogenic in humans also replicate in other 
organisms ranging from mosquitos to chimpanzees; however, infection in 
these other hosts is often less pathogenic and symptomatic. Often 
analogues of human viral infections exist in other species and useful 
comparisons can be made. In contrast to humans, these analogous 
infections may not cause disease yet important information can be learned 
from studying the presumed adaptations, either by the host or the virus, 
 2 
that confer reduced pathogenesis. While these model systems have the 
potential to teach about important features of infections of humans, direct 
understanding of the pathogenesis of viral infections in humans remains 
challenging because it is unethical to perform the experiments used to 
describe the biology of infection and pathogenesis in other hosts.  For this 
reason in particular, this thesis explores novel methods of data collection 
and analysis from naturally occurring human viral infections to fill in 
knowledge gaps regarding infection in this context.  
 
The natural history of hepatitis C virus. 
HCV is a hepatotropic single-stranded positive-sense RNA virus 
that infects over 170 million people worldwide. Acute HCV infection 
progresses to chronic infection in ~75% of cases (3–5). Of those who 
become infected, a large fraction will never experience any symptomatic 
manifestations of their disease; however, many will progress through a 
disease course characterized by chronic inflammation and the progressive 
deposition of fibrotic tissue within the liver, ultimately resulting in cirrhosis 
and, in some, end-stage liver disease and hepatocellular carcinoma. 
Very little is understood about why certain individuals progress 
along a particular branch point in the natural history of infection. The most 
notable predictors are co-infection with HIV, IFNL3 genotype, age, race, 
and gender; however, they collectively explain only a minority of the 
natural variation observed. Chimpanzees (Pan troglodytes) and northern 
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treeshrews (Tupaia belangeri) remain the only known organisms besides 
humans to support HCV replication naturally. While interesting surrogates 
for HCV infection in humans, their biological relevance and practicality 
have made them unpopular. Curiously, relatively high rates of 
spontaneous resolution and low levels of liver inflammation and disease 
occur with HCV infection of chimpanzees when compared to humans. 
Recently, national policy changes regarding the use of chimpanzees in 
research have disfavored their use in this setting. Overt pathogenesis has 
been observed with HCV in northern treeshrews (6); however, very rarely 
is sustained viremia observed and they are difficult to breed in captivity. 
Without a representative animal model for HCV, observation and 
molecular dissection of naturally occurring infections has the highest 
potential for illuminating biology that occurs at the system level such as 
pathogenesis.   
 
The natural history of human immunodeficiency virus-1.  
HIV-1 is a lentivirus that infects over 33 million people worldwide 
(7). If left untreated, infection with HIV leads to the acquired-
immunodeficiency syndrome (AIDS) characterized by a dysfunctional 
immune system that renders the host more susceptible to life-threatening 
opportunistic infections and malignancy. Initial infection is asymptomatic in 
many cases but in some, manifests in a mononucleosis-like illness; during 
this acute stage high amounts of virus can be found in the blood. CD4+ T-
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cells become infected at an exponential rate, and their resulting death 
causes a precipitous drop in their abundance in the blood (~50%). Though 
the host’s immune system rarely controls infection to very low or 
undetectable amounts of virus, the host limits replication by ~10-100-fold 
within a few months and CD4+ T-cell abundance begins to rebound. In 
this asymptomatic phase, CD4+ T-cell counts remain depressed 
compared to pre-infection levels as replication continues. Eventually the 
destruction of CD4+ T-cells outpaces the host’s ability to produce them 
and their numbers drop, leaving the host vulnerable to the infections and 
malignancies that define AIDS.  
Lentiviruses similar to HIV exist for non-human primates and are 
referred to as simian immunodeficiency viruses (SIV). In their natural 
hosts, these viruses rarely cause immunodefficiency. Interestingly, when 
the variant of SIV that infects one primate species is introduced into 
another species of primate, disease features similar to AIDS in humans 
may emerge. Studying these model infections has revealed numerous 
insights into how immunodeficiency arises; however, extrapolation of 
these interactions to the biology of HIV infection in humans is difficult 
given the important differences that exist between the hosts and the 
viruses.  
As we will discuss in chapter three, some of the most informative 
genetic interactions between humans and HIV-1 are interferon-induced 
immune genes that restrict viral production in host cells. Strong evidence 
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exists that genes that are associated with the immune system are some of 
the most rapidly changing genes in mammalian genomes(8). As such, 
many of the genetic interactions between host and virus may be not 
informative in the context of non-human primates. As was the case with 
HCV, limited experimental options and the distinct host-pathogen 
interactions in humans underscore the importance of studying molecular 
interactions between virus and host in the natural infection. 
 
Studying humans  
For the reasons discussed above and more, investigation of 
humans infected with HCV or HIV is necessary to understand the 
interactions (genetic or otherwise) that occur between host and pathogen. 
There are many approaches one can take to making these sorts of 
associations in humans with a viral infection. One approach is to profile 
many individuals currently infected, detail all of their relevant metrics, and 
survey these parameters for associations. This approach also referred to 
as cross-sectional, has the advantage of relatively simple data collection 
enabling the investigator to assemble large amounts of data at once to 
make important associations, especially when resources and time are very 
limited. This approach is not without limitations. Most importantly, because 
people are so different from one another prior to infection, large numbers 
of individuals must be observed so that changes associated with the 
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infection can be appreciated amidst these person-to-person differences 
unrelated to infection. 
Another approach is to follow people longitudinally. Although 
resource intensive, cohort-based investigation allows the investigator to 
account for person-to-person differences in baseline gene expression by 
enabling the measurement of changes that occur through infection or 
treatment. As such, many fewer samples are needed to make significant 
associations. If for instance, gene A is induced by infection with HCV but 
its baseline expression varies dramatically from person to person, one can 
sample a person before and after infection and examine the change in the 
expression of gene A to determine if its expression is significantly 
associated with HCV infection. On the other hand, many more uninfected 
and infected people would need to be profiled cross-sectionally to 
appreciate a difference in levels of gene A between infected and 
uninfected individuals. Also, longitudinal data allows for more inference 
about causality, since temporal structure exists (a key postulate of 
causality). Another feature of longitudinal sampling is that it systematically 
adjusts for all of the variables that are not measured since those variables 
are largely constant over short durations in the same people. In chapters 
one and three we will use longitudinal sampling strategies to understand 
how infection- or treatment-induced changes can reveal potentially 
important genetic features of the host. 
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In chapter one, we will sample individuals throughout differing 
courses of acute infection with HCV and examine microRNA expression 
changes in plasma and uncover novel features of these regulatory 
molecules that arise in infection. In chapter two, we will examine naturally 
occurring variation in HCV envelope sequence and sensitivity to broadly 
neutralizing antibodies (key molecules for vaccine design) and identify an 
unexpected route of resistance. Finally in chapter three, we will compare 
HIV-1 virus dynamics with gene induction in response to interferon alpha 
treatment to identify novel restriction factors for HIV-1.  
 8 
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CHAPTER 1: Acute HCV infection induces 
consistent changes in circulating miRNAs that are 
associated with non-lytic hepatocyte release 
Abstract 
Plasma microRNAs (miRNAs) change in abundance in response to 
disease, and have been associated with liver fibrosis severity in chronic 
hepatitis C virus (HCV) infection.  However, the early dynamics of miRNA 
release during acute HCV infection are poorly understood. In addition, 
circulating miRNA signatures have been difficult to reproduce among 
separate populations.  We studied plasma miRNA abundance during 
acute HCV infection to identify a miRNA signature of early infection. We 
measured 754 plasma miRNAs by quantitative PCR array in a discovery 
cohort of 22 individuals before and during acute HCV infection and after 
spontaneous resolution (n=11) or persistence (n=11) to identify a plasma 
miRNA signature. The discovery cohort derived from Baltimore Before and 
After Acute Study of Hepatitis. During acute HCV infection, increases in 
miR-122 (P<.01) and miR-885-5p (Pcorrected<.05) and a decrease in miR-
494 (Pcorrected<.05) were observed at the earliest time-points after virus 
detection. Changes in miR-122 and miR-885-5p were sustained in 
persistent (P<.001) but not resolved HCV infection. The circulating miRNA 
signature of acute HCV infection was confirmed in a separate validation 
cohort that derived from the San Francisco-based UFO Study (n=28). As 
further confirmation, cellular changes of signature miRNAs were examined 
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in a tissue-culture model of HCV in hepatoma cells: HCV infection induced 
extracellular release of miR-122 and miR-885-5p despite unperturbed 
intracellular levels. In contrast, miR-494 accumulated intracellularly 
(P<.05). Collectively, these data are inconsistent with necrolytic release of 




Hepatitis C virus (HCV) is a single-stranded positive-sense 
hepatotropic RNA virus that infects over 170 million people worldwide. 
Acute HCV infection progresses to chronic infection in ~75% of cases (3–
5). Little is understood about early host-pathogen interactions due to a 
lack of representative animal models and the difficulty in studying acute 
HCV, which is largely asymptomatic. 
MicroRNAs (miRNAs) are 18-25 nucleotide non-coding RNA 
molecules with widespread gene-network regulatory capacity.  miRNAs 
are readily detectable in cell-free components of blood, and circulating 
extracellular miRNAs have been associated with the severity and 
progression of numerous human diseases including hepatocellular 
carcinoma (HCC) (9, 10), liver injury (11), colorectal cancer (12), and 
cardiac injury (13). Little is understood about the early dynamics and 
release of circulating miRNAs in specific disease conditions.  Importantly, 
circulaing miRNA signatures have been challenging to confirm in separate 
cohorts, raising questions as to whether consistent changes in circulating 
miRNAs occur (14, 15). 
miRNAs have profound intracellular effects, and have been 
described to play a role in viral pathogenesis (16, 17). Indeed, HCV 
replication requires the hepatocyte-specific miRNA miR-122 for efficient 
replication (18), and a miR-122 antagonist was shown to have potent 
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antiviral effects in a human trial (19). Whereas conventional wisdom 
predicts that extracellular miRNAs found circulating in the plasma are the 
result of cell lysis, extracellular miRNAs have been shown to be selectively 
secreted by “donor” cells and can regulate genes in target cells in animal 
and tissue culture models (20–30). We hypothesized that acute HCV 
infection leads to regulated changes in the abundance of circulating 
microRNAs. We used multiple approaches to validate the circulating 
miRNA signature.  
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Materials and Methods 
Figure 1-1. Study design. miRNAs were quantified in plasma samples from injection 
drug users in the discovery cohort who acquired acute HCV infection and either cleared 
infection (clearers; n=11) or developed persistent infection (persisters; n=11). miRNAs 
were also quantified in plasma samples from 3 participants in the discovery cohort who 
did not develop infection and who had available samples at time intervals that closely 
matched the intervals in the acutely infected participants. A separate validation cohort 
(n=28) was studied to confirm the findings in the discovery cohort.  
 
Study population. The principal measurements in this study were 
performed using samples from a discovery cohort. Major findings were 
confirmed in a separate validation cohort.  The discovery cohort was 
composed of 22 participants in the Baltimore Before and After Acute Study 
of Hepatitis (BBAASH) cohort, an ongoing study of injection drug users 
(IDU) who are at high risk for acquiring HCV infection (4). Eligible 
participants have a history of injection drug use and are negative for anti-
HCV antibodies and HCV RNA at the time of enrollment. All enrollees are 
assessed for HBV and HIV status at enrollment, vaccinated for HBV if no 
evidence of previous vaccination, and monitored regularly for 
seroconversion at regular intervals as previously described. Written 






















receive counseling to reduce drug use and its complications. Phlebotomy 
is performed monthly, as previously described (4). Participant infection 
status is monitored by quantitative PCR (qPCR) for HCV RNA, and those 
with acute HCV infection are referred for evaluation for treatment.  The 
validation cohort was composed of 28 participants in the San Francisco-
based UFO Study (You Find Out), a prospective study of young IDU at 
high-risk for acquiring HCV infection in whom incident acute HCV infection 
is identified and followed monthly (31). Written consent was obtained from 
each participant. The Institutional Review Board (IRB) of Johns Hopkins 
University School of Medicine approved the BBAASH study, and the IRB 
of the University of California at San Francisco approved the UFO Study. 
 
Sample selection. Plasma samples were selected from participants for 
whom acute HCV infection and its outcome were fully documented. Four 
samples were examined over structured time intervals for each participant 
in the discovery cohort (Figure 1-1): time I) pre-viremia, defined by 
negative HCV RNA and anti-HCV antibody; time II) initial viremia, defined 
by the first positive HCV RNA test; time III) late acute infection, defined by 
the last available viremic plasma sample from persons who cleared 
infection (clearers) and a time-from-initial viremia-matched sample from 
persons with persistent infection (persisters); and time IV) post-viremia, 
defined by HCV RNA negative values ≥ 2 consecutive visits more than 4 
weeks apart in clearers and a time-from-initial viremia-matched sample in 
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persisters. An additional 3 participants from the BBAASH study were 
included as negative controls.  The negative control participants were 
injection drug users in whom HCV infection was never detected, and 
plasma samples were examined that corresponded to the same structured 
time intervals as in the discovery cohort to control for the natural variation 
in abundance of miRNAs over time. For confirmation of the principal 
findings, two samples were selected from each of the 28 individuals in the 
validation cohort: time I) pre-viremia, defined by negative HCV RNA and 
anti-HCV antibody; and time II) initial viremia, defined by the first HCV 
RNA positive sample within 8 months of incident HCV infection. 
 
HCV RNA quantification. HCV RNA levels in plasma samples were 
previously quantified using a commercial RT-qPCR assay (TaqMan® HCV 
analyte-specific reagent, Roche Molecular Diagnostics, USA), which has a 
lower limit of quantification (LLOQ) of 50 IU/mL. Samples with detectable 
HCV RNA that were below the LLOQ were assigned a value of 25 IU/mL, 
and detection was confirmed using a nested PCR for the Core-E1 region 
of HCV as previously published (32). 
 
miRNA isolation and quantification. RNA was isolated from 100 µL of 
plasma according to the miRvana Total RNA isolation protocol for plasma 
samples (Life Technologies). Prior to isolation, 5 ng of glycogen was 
added as a carrier polymer as previously described (33), and 0.5 pg of 
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Arabidopsis thaliana miRNA ath-miR159a 
(UUUGGAUUGAAGGGAGCUCUA, Integrated DNA Technologies) was 
added as an extraction control. 
After extraction, RT/qPCR-based TaqMan® OpenArray® chips 
were used to quantify 754 miRNAs using Human MicroRNA Panel (Pool A 
v2.1 and Pool B v3.0) on the QuantStudio® 12K Flex machine (Life 
Technologies) at the Genetic Resources Core Facility, Johns Hopkins 
Institute of Genetic Medicine, Baltimore, MD. Ct values from the 
QuantStudio® machine that did not exceed 35 (the array-wide validated 
limit of quantitation) were exported using the ExpressionSuite® (Life 
Technologies) software. Array data were deposited on Gene Expression 
Omnibus (http://www.ncbi.nlm.nih.gov/geo; accession ID: GSE61187). 
Quantile normalization for arrayed data was performed, as has been 
previously described using the ‘limma’ package version 3.24.3 in R 
(www.r-project.org) version 3.1.2 (34–36). 
The qPCR array was separately validated by performing individual 
RT/qPCR assays in duplicate for ath-miR-159a, miR-122, and miR-885-5p 
using the microRNA Taqman® assay. Fold change values between 
longitudinal samples were computed using the 2ΔΔCt method against ath-
miR-159a, and by using the 2ΔCt method in the quantile-normalized 
approach with agreement between the two methods for all miRNAs for 
which results are presented. Quantile normalized data is presented. 
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In vitro HCV infection. A serum-free preparation of the J6/JFH-1 
infectious clone of HCV (HCVcc) was produced by isolating serum-free 
supernatants from cells that were transfected with HCV RNA. Briefly, the 
pUC19-J6/JFH1 plasmid was linearized using Xba1 (New England 
Biolabs) and RNA was synthesized in vitro using the T7-polymerase 
based RiboMAX kit (Promega). Phenol-chloroform purified RNA was 
transfected into Huh 7.5.1 cells using DMRIE-C reagent (Life 
Technologies) according to the manufacturer’s protocol. Cells were 
cultured in Dulbecco’s Modified Eagle Medium supplemented with 10% 
fetal bovine serum until 24 hours post-transfection. Serum-containing 
media was removed at 24 hours, cells were washed with PBS twice, and 
media was replaced with Ultraculture serum-free media (Biowhittaker). 
Serum-free supernatants from infected cells were collected 5-days post 
transfection, centrifuged at 1,500 x g for 15 minutes and passed through a 
0.22 µm filter to remove cellular debris. HCV RNA was quantified using 
the protocol described above. Mock virus preparations were produced 
using the same protocol except no HCV RNA was added to the DMRIE-C 
transfection. 
Serum-free cultured Huh 7.5.1 cells were infected with the serum-
free HCVcc preparation at a multiplicity of infection of 5 IU/cell. 
Supernatants were centrifuged at 1,500 x g for 15 minutes and passed 
through a 0.22 µm filter to remove cellular debris.  Supernatant and 
cellular miRNAs were isolated using the miRvana® PARIS and miRNA 
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isolation systems, respectively (Life Technologies), according to the 
manufacturer’s protocol.  
 
In vitro HCV infection with miRNA inhibition and over-expression. 
Seed cultures of Huh 7.5.1 cells were transfected with microRNA 
miRvana® mimics and inhibitors (Life Technologies) at a final 
concentration of 40nM using Oligofectamine (Life Technologies). Two 
days after transfection, cells were infected with HCVcc at a multiplicity of 
infection of 10 IU/cell. HCV RNA was quantitated 48 hours after infection 
in supernatants and after cell lysis. Immunohistochemistry for HCV was 
also performed at 48 hours after infection. Cells were fixed with 4% 
formaldehyde for 20 minutes then stained for HCV using the 9E10 anti-
NS5A antibody (37) at 1:500 dilution in PBS + 3% bovine serum albumin + 
0.3% Triton X-100 for one hour at room temperature.  Cells were washed 
twice with PBS and stained using secondary antibody FITC-conjugated 
goat anti-mouse IgG (Life Technologies) at 1:1000 dilution in PBS + 3% 
bovine serum albumin + 0.3% Triton X-100 for one hour at room 
temperature.  Cells were washed twice in PBS then imaged with a Zeiss 
inverted microscope with an Olympus camera. 
 
Focus counting analysis. Cells were transfected, fixed, and stained as 
described above except that infection was performed using 4 IU/cell to 
facilitate focus counting. Images were acquired and foci were counted 
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using an AID iSpot Reader Spectrum operating AID ELISpot Reader 
version 7.0 at the Johns Hopkins Sidney Kimmel Comprehensive Cancer 
Center Immunology Core, Baltimore, MD. 
  
Figure 1-2. Quantitative PCR array performance characteristics indicate that 
miRNA quantification and detection was unbiased. (A) The number of microRNAs 
detected per sample and (B) the median qPCR crossing threshold (Ct) values among all 
measured miRNAs per sample are shown across all time points. (C) Median Ct values of 
the externally added control miRNA ath-miR-159a for all samples. Ath-miR-159a was 
separately included on each array > 10 times to improve the precision of its 
measurement. (D) miRNAs were ordered by their detection frequency (100*the number of 
samples in which a miRNA was detected divided by the total number of samples) in all 
samples from participants  in the discovery cohort who developed acute HCV infection: 






















































































































































Statistical analysis. To avoid false discovery due to incomplete coverage, 
only microRNAs that were detected at a frequency of greater than 70% 
across all samples were selected for analysis (Figure 1-2D). Two-tailed 
Wilcoxon rank-sum tests were performed when appropriate. Pearson’s 
correlation was used to detect associations between continuous variables.  
Multiple comparisons correction was performed according to the 
Benjamini–Hochberg method (38). Ten microRNAs (including miR-122, 
miR-885-5p, and let-7b) were pre-specified before analysis for their 
relevance to HCV biology; correction for multiple comparisons was not 
employed for these microRNAs. Statistical analysis was performed using 














Age,* median (min-max) 25 (19-31) 23 (16-28) 29 (29-31) 
White, n (%) 20 (91) 18 (64) 2 (67) 
Female, n (%) 15 (68) 10 (36) 2 (67) 
HCV genotype,* n (%)    
    1a 16 (73) 11 (39) - 
    1b 2 (9) 2 (7) - 
    2 1 (5) 5 (18) - 
    3a 3 (14) 10 (36) - 
IFNL3 (rs12979860) genotype, n (%)    
    C/C 11 (50) 10 (36) NP 
    C/T 9 (41) 15 (54) NP 
    T/T 2 (9) 3 (11) NP 
ALT U/L,* median (IQR) 41 (26-241) 38 (19-
83.25) 
NP 
HCV RNA (log10IU/mL),*median (IQR) 6.3 (5.3-6.7) 5.8 (4.97-
7.22) 
undetectable 
Days infected,*† median (IQR) 26 (17-46) 46 (39-96) - 
*At initial viremia 
†Imputed infection date is the mid-point between the last known aviremic and first known 
viremic dates 
“-“ indicates that this was not applicable. 
“NP” indicates that the measurement was not performed. 
“undetectable” indicates that all samples over the sampling interval were below the lower 
limit of detection. 
 
Study and array characteristics. The median (IQR) days-infected at 
initial viremia in the discovery cohort was 26 (17-46), the median (range) 
age was 25 years old (19-31), 20 (91%) were white, and 15 (68%) were 
female (Table 1-1).  The median (IQR) HCV RNA level upon initial viremia 
was 6.3 log10 IU/mL (5.3-6.7) and the median (IQR) ALT was 41 U/L (26-
241). HCV genotype 1a was present in 16/22 (73%) participants, followed 
by genotype 1b in 2/22 (9%), genotype 2 in 1/22 (4.5%), and genotype 3 
in 3/22 (13.6%). Although the discovery and validation cohorts both 
represent the natural history of acute HCV (39–42), the main differences 
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between them were race and IFNL3 genotype: 18 (64%) of the validation 
cohort was white and only 10 (36%) were IFNL3 (rs12979860) genotype 
C/C.  In addition, the median (IQR) imputed number of days infected in the 
discovery cohort was 26 (17-46) days and 46 (39-96) days for the 
validation cohort (Table 1-1). None of the subjects included in either 
cohort had evidence of infection with HIV or HBV over the course of the 
sampling interval.  
A median (range) of 303 miRNAs (180-386) was detected per 
sample: 108 miRNAs were detectable in > 98% of samples, and 468 
miRNAs were detectable in ≤ 50% of samples. The analysis was limited to 
the 243 interpretable miRNAs that were detectable in greater than 70% of 
all samples. No significant differences were found in the number of 
miRNAs detected per sample, the un-normalized array median Ct values, 
or in the extraction efficiency of samples across the sampled time points 
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Figure 1-3. Acute HCV infection results in an increase in circulating miR-122 and 
miR-885-5p and a decrease in circulating miR-494.  (A) A volcano plot depicts the 
median change in abundance of each miRNA across 22 participants between pre-viremia 
and initial viremia in the x-axis (miRNAs that are increased at initial viremia compared to 
pre-viremia are to the right of the graph).  The y-axis shows the uncorrected p-value of 
the change in miRNA abundance. miRNAs in blue were significantly different between 
pre- and initial viremia in the discovery cohort after correction for multiple comparisons; 
no correction, however, was applied for miR-122, which was pre-specified in the study 
design for its relevance to HCV biology. (B) The change in circulating miRNA abundance 
versus pre-infection in matched time-intervals is displayed for BBAASH participants who 
were HCV negative (black) and who acquired acute HCV infection (green and orange 
lines). The selected time points were determined by participants who acquired HCV: 
before infection (pre-infection), during acute infection in the earliest (initial viremia) and 
latest (time III) available samples, and either after infection in clearers (green; n=11) or 
during the transition to chronic infection in persisters (orange; n=11) (time IV). Shown are 
changes in miRNA abundance from baseline in all 22 individuals in the discovery cohort 
for miR-411, miR-494, miR-122, and miR-885-5p.  (C) In the x-axis is shown the change 
in abundance of miR-494, -122, and -885-5p between pre-infection and initial viremia.  In 
the y-axis is shown the contemporary plasma log10 HCV RNA levels (IU/mL) at initial 




Figure 1-4. Validation of qPCR array results using individual RT/qPCR assays for 
select miRNAs. (A) miR-122 and (B) miR-885-5p abundance at pre-infection and initial-
viremia time points for all infected individuals in the discovery cohort were confirmed 
using individual RT/qPCR Cts; qPCR array results compared favorably with individual 
RT/qPCR results (r>0.97, p<2.2*e-16 for both). 
 
A circulating miRNA signature of acute HCV infection. With the onset 
of viremia, the abundance of four plasma miRNAs significantly changed 
(Figure 1-3A); the changes in abundance were not associated by their 







































constitutive expression in liver. Extracellular circulating miR-494, the 
second most abundant miRNA in the liver, and miRNA-411 decreased to a 
median (IQR) of 0.48-fold (0.19-0.78) and 0.24-fold (0.15-0.61), 
respectively (Pcorrected<.05 for each), compared to pre-infection levels; both 
miRNAs decreased in 15/22 (68%) participants. In contrast, circulating 
levels of miR-122, the most abundant miRNA in the liver, rose a median 
(IQR) of 5.3-fold (1.5-39.2; P<.01) over pre-infection levels, and increased 
levels were noted in 16/22 (73%) participants.  miR-885-5p rose a median 
(IQR) of 9.0-fold (2.4-130.2; P<.001), and increased levels were noted in 
19/22 (86%) participants. We confirmed that amplification scores for miR-
494, -411, -122, and 885-5p were above 1.2, the accepted threshold.  In 
addition, the changes in abundance of miR-122 and -885-5p were 
individually confirmed using separate RT/qPCR assays and correlated 
tightly with the results from the qPCR array (Figure 1-4).  
   
Figure 1-5. Validation of the plasma miRNA signature of acute HCV in a separate 
cohort. Boxplots with individual values show the changes in circulating miRNA 
abundance for miR-411, miR-494, miR-122, and miR-885-5p between pre-viremia and 
initial viremia in 28 participants of the UFO study.  P-values generated by the non-












































The extracellular miRNA signature was confirmed in a validation cohort of 
28 participants in the San Francisco-based UFO study (Table 1-1). 
Changes in circulating miR-494, -122, and -885 with HCV infection were 
consistently observed in the validation cohort: miR-494 levels decreased a 
median (IQR) of 0.43 fold (0.19, 1.7; P<.05), miR-122 levels rose a 
median (IQR) of 2.3 fold (0.9-4.7; P<.05), and miR-885-5p rose a median 
(IQR) of 1.5 fold (0.9-3.25; P<.05). Changes in miR-411 were not 
consistently observed and so this miRNA was not studied further (Figure 
1-5). 
To determine whether the extracellular miRNA signature of acute 
HCV infection persisted during HCV viremia, miRNA abundance was 
quantified until the resolution of infection (clearers) or until early chronic 
infection (persisters)(Figure 1-3B). Four samples were taken from each 
person: i) pre-infection (negative HCV RNA and antibody tests); ii) initial 
viremia (first positive HCV RNA test); iii) time III (the last viremic visit in 
clearers and a time-from-initial viremia-matched sample from persisters); 
and iv) time IV (HCV RNA consistently negative on ≥ 2 consecutive visits 
more than 4 weeks apart in clearers and a time-from-initial viremia-
matched sample in persisters). miR-494 levels decreased transiently at 
initial viremia, but were not significantly different from pre-infection levels 
at later time points (Figure 1-3B). In contrast, miR-122 and miR-885 
levels were persistently elevated for the duration of viremia, returning to 
pre-infection levels at time IV in clearers, but remaining elevated in 
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persisters (P<.001) (Figure 1-3B). To verify that the extracellular miRNA 
signature was not the result of fluctuations over time that are unrelated to 
acute HCV infection, levels of miRNAs that constituted the signature were 
also examined in 3 IDUs in the BBAASH cohort who did not contract HCV 
over the course of their participation in the study. Plasma samples from 
uninfected IDUs were matched for intervals that were comparable with 
those observed in the discovery cohort (Figure 1-3B): no consistent 
changes in abundance were noted over time for miR-494, miR-122, and 
miR-885-5p among the 3 uninfected IDUs, further underscoring the 
findings in acute HCV infection.   
 
Figure 1-6. The circulating microRNA signature of acute HCV infection does not 
reflect intrahepatic miRNA abundance. (A) The change in circulating miRNA 
abundance from pre- to initial viremia for each of 185 miRNAs (y-axis) was compared to 
the intrahepatic abundance of the same miRNAs (x-axis), based on previously published 
data (43). When miR-122, the most abundant intrahepatic miRNA, was included, there 
was a statistically significant but weak correlation between intrahepatic abundance and 
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the change in circulating abundance of all studied miRNAs (r=0.19; P=.001). The 
relationship was lost when miR-122 was excluded from the analysis r=-.04,p=.46). (B) 
The relative circulating abundance of miR-885-5p, miR-192, miR-494, and miR-122 was 
compared to contemporaneous ALT levels at pre-(black) and initial (red) viremia and 
presented in order of their intrahepatic abundance. Regression lines and their 




Figure 1-7. Plasma miRNA abundance is not related to intrahepatic miRNA 
abundance. The plasma miRNA abundance at initial viremia for each of 70 miRNAs (y-
axes) was compared to the intrahepatic abundance of the same miRNAs (x-axes), based 
on previously published data.  
 
We further investigated whether there were predictors of the 
circulating miRNA signature, first by testing whether its components were 
related to contemporary HCV RNA levels.  While we observed no 
relationship between HCV RNA levels and the change in abundance of 
miR-494, we found inverse associations with miR-122 (r=-0.56, P=0.0065) 
and miR-885-5p (r=-0.5, p=0.02)(Figure 1-3C). These associations were 
only observed during the initial viremia time point.  Next, we used two 
approaches to consider the role of hepatocyte damage in producing the 
extracellular miRNA signature. First, we adapted data from Tzur et al. 
describing the abundance of 185 miRNAs in human livers that were also 
profiled in our study (43). We found no relationship between intrahepatic 
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acute HCV infection (r=-0.04,P=.46; Figure 1-6A). Similarly, we applied 
data from 148 miRNAs examined by Randall et al. to our study and did not 
detect a relationship between liver abundance and change in plasma 
abundance after accounting for miR-122 (r=-0.09,P=.28; Figure 1-7) (44). 
The second approach we used to study the role of hepatocyte 
damage in the extracellular miRNA signature was to examine associations 
with aminotransferases: while miR-122 and miR-885 were associated with 
contemporaneous ALT levels, miR-494 had no association with ALT 
despite its reported intrahepatic abundance (Figures 1-6 and 1-7).  
Conversely, miR-192, which has been reported as being increased and 
related to ALT levels in necrolytic drug-induced liver injury (45, 46), was 
not significantly elevated or associated with ALT levels in our study 
(Figure 1-6B).  Taken together, these results suggest that changes in 
extracellular miRNA abundance are not solely the result of cell lysis. 
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Figure 1-8. Infection in vitro recapitulates the observed signature of circulating 
miRNAs in acute HCV infection in vivo. (A) Huh 7.5.1 hepatoma cells were infected 
with the J6/JFH-1 infectious clone of HCV (HCVcc) and compared to uninfected cells 
(mock).  All cell cultures and virus were prepared using serum-free to avoid confounding 
measurement of highly conserved miRNAs in fetal bovine serum. After 24 hours, cells 
were washed and the media replaced. Five days following infection, the ratio of the fold 
change of miRNAs in supernatants to fold-change within cells (B) shows the relative 
enrichment or depletion of miRNAs in supernatants relative to cells. Cellular (C) and 
supernatant (D) abundance of miRNAs were normalized to intracellular snRNA U6 
abundance. Error bars indicate the standard deviation of four replicate infections and 
asterisks indicate significant (P<0.05) changes from mock controls. 
 
The miRNA signature of acute HCV infection in vitro. To support that 
hepatocytes, and not other cells, contribute to the miRNA signature of 
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and quantified the expression of miRNAs in cells and supernatants, 
comparing these amounts to uninfected cells that were cultured for the 
same number of days (Figure 1-8A). Quantities of extracellular miRNAs 
were normalized to intracellular amounts of the same miRNAs to control 
for cell-death present in test and control wells.  The extracellular signature 
that was found in circulating human plasma was confirmed in vitro: miR-
122 and -885 increased outside of cells relative to inside, while miR-494 
decreased (Figure 1-8B). Interestingly, intracellular miR-122 and miR-
885-5p abundance did not vary with infection (Figure 1-8C) while 
extracellular levels significantly increased (P<.05 for both, Figure 1-8D). In 
contrast, the relative decrease in extracellular miR-494 abundance largely 
resulted from intracellular accumulation (Figure 1-8C).   Collectively, 
these results suggest that the release or retention of the miRNAs that 




Figure 1-9. Circulating miR-122, let-7b, and miR-551b are associated with plasma 
HCV RNA abundance in acute infection. (A) Pearson’s correlation P-values are plotted 
for fold change of each miRNA over pre-infection and HCV RNA abundance at acute 
viremia. Blue points indicate miRNAs with significant relationships with HCV RNA either 
after correction for multiple comparisons (miR-551b) or P<0.05 for miRNAs with known 
impacts on HCV replication (miR-122 and let-7b).   (B) Scatterplots indicate the 
association between plasma HCV RNA levels and the relative abundance of let-7b (upper 
panel) and miR-551b (lower panel). Regression line and corresponding Pearson’s 
correlation coefficient is included. (C) Intracellular HCV RNA normalized to cellular RNA 
input from HCVcc infected Huh 7.5.1 cells transfected with indicated miRNA inhibitors or 
mimics is shown. Error bars indicate standard deviations between four repeat 
transfections and asterisks indicate significant changes in HCV RNA when compared to 
the negative control siRNA (siCNTRL). (D) Foci of infection, immunostained for HCV 
NS5A, were quantified from HCVcc infected Huh 7.5.1 cells under the labeled conditions. 
(E) Representative images from source wells used for (D) showing NS5A in green and 
nuclei (DAPI) in blue. 
 
Extracellular miRNAs and plasma HCV RNA abundance.  High HCV 
RNA levels during early acute infection have been found to be associated 
with spontaneous clearance (47). To understand potential determinants of 
HCV viremia in acute HCV infection, we examined changes in abundance 
































































































































































at initial viremia  (Figure 1-9A), adjusting for multiple comparisons.  The 
change in abundance of extracellular miR-551b was the most strongly 
associated with contemporaneous plasma HCV RNA levels (r=0.73; 
Pcorrected=0.04; Figures 1-9B), although the median (IQR) amplification 
scores for miR-551b were 0.968 (0.899-1.024). As we found earlier, HCV 
RNA levels were inversely associated with plasma levels of miR-122 
(Figure 1-3C). In addition, we found an inverse association between HCV 
RNA levels and let-7b (r=-0.59; P=.005), a miRNA that is induced by type 
1 and 3 interferons and has anti-viral properties in vitro (48, 49). 
 To establish if miR-551b directly impacts HCV replication in 
hepatocytes, we transfected Huh 7.5.1 hepatoma cells with a miR-551b 
inhibitor and mature miR-551b mimic separately: miR-551b inhibition 
resulted in a significant increase in HCV RNA (P<0.05), while the miR-
551b mimic led to a decline in HCV RNA abundance (P<0.05;Figure 1-
9C).  By comparison, miR-122 inhibition led to more potent suppression of 
HCV RNA levels. Transfection efficiency in these experiments was 81.5% 
± 1.3%, and was measured using FITC-conjugated scrambled 
oligonucleotide. 
We confirmed the HCV RNA findings by quantifying HCV protein 
expression.  Cells were transfected with a miR-551b mimic, inhibitor, and 
a scrambled siRNA, then infected with HCV, and finally immunostained for 
the HCV NS5A protein.  Cells that were treated with the miR-551b mimic 
showed a decrease in the number of infected cells when compared to the 
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scrambled siRNA control, while miR-551b antagonism led to an increase 
in the number of infected cells (Figures 1-9D and 1-9E).  Focus counting 
revealed a significant decrease (P<0.05) in the number of foci in cells 
transfected with the miR-551b mimic, however, the increase in the number 
of foci observed in cells transfected with the miR-551b inhibitor did not 
reach significance (P=0.1) (Figure 1-9D).  
 
Figure 1-10. Changes in miRNA abundance did not significantly differ by IFNL3 
genotype or infection outcome. Fold-changes between pre-infection and initial viremia 
were separated into groups according to (A) IFNL3 genotype or (B) infection outcome 
and each group was assigned a median fold change (n=11 for CC, nonCC [CT or TT], 
clearers, and persisters). The volcano plots depict the differences in the median fold-
changes between each group in the x-axes in the form of a ratio (higher fold-change in 
the non-CTs or persisters to the left). In the y-axis is shown the uncorrected p-value of 
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By comparing plasma miRNA levels in a well-characterized cohort 
before, during, and after acute HCV infection, we identified a consistent 
and specific extracellular miRNA signature of acute infection that was 
confirmed in a separate cohort and in vitro.  Contrary to conventional 
wisdom, circulating miRNA abundance during acute infection did not 
simply represent cellular necrosis but a nonrandom process of retention 
and release that correlates with the onset and control of virus infection.    
miR-122 is the most abundant miRNA in the liver; its increase in 
plasma levels during chronic infection has been presumed to be 
analogous to elevated serum aminotransferase levels, that are a 
consequence of cellular necrosis. However, miR-494, the second most 
abundant miRNA in the liver profiled, decreased in the plasma of acutely 
infected persons, and was found to increase intracellularly upon infection. 
We also confirmed that there was no association of acute HCV infection 
with plasma abundance of miR-192, a liver abundant microRNA that has 
been found to be increased in circulation during drug-induced liver injury 
(45, 46) and steatohepatitis (50). Taken together, these findings are 
inconsistent with necrolytic release of miRNAs, and implicate selectivity in 
the release of cellular miRNAs that determines their plasma abundance.  
Our miRNA isolation technique does not distinguish between free, 
exosome-associated, or virion-associated miRNAs. The observed 
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increase in abundance of extracellular miR-122 upon HCV infection is 
consistent with the recent observations that miR-122 is packaged along 
with HCV RNA in exosomes (51). Moreover, the inverse relationship 
between circulating miR-122 and plasma HCV RNA levels suggest that 
miR-122 is not packaged directly into virions. Future research should 
focus on how miRNAs are differentially released and compartmentalized. 
Circulating miRNA profiles have been associated with HCV 
infection in previous studies, although many of these studies were 
performed in persons with long-term chronic infection in whom liver 
fibrosis may have also contributed to miRNA abundance (52, 53). For 
example, changes in circulating miR-122 abundance have been reported 
in persons with chronic HCV infection and also in drug-induced liver injury 
(45) and non-alcoholic steatohepatitis (52). In addition, serum miR-122 
levels in persons with chronic HCV infection who were treated with 
interferon and attained a sustained virologic response were higher than 
persons who had a null response (54, 55), and these results were largely 
explained by the genetic susceptibility marker near the IFNL3 gene.  In 
contrast, we did not find an association between the change in miR-122 
levels upon acute infection and the outcome of infection or IFNL3 
genotype (Figure 1-10), although our sample size was not powered for 
this question. Given that there is an established positive association 
between HCV clearance and peak HCV RNA abundance (47), and that we 
found a negative relationship between circulating miR-122 and HCV RNA, 
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it is logical to speculate that the association between circulating miR-122, 
IFNL3, and HCV clearance may be consistent with what was observed 
during interferon treatment responses. However, we acknowledge that 
conclusive proof would require study of a larger cohort. We also note that 
we did not find changes in the abundance of miR-20a and miR-92a, in 
contrast to a previous report of miRNAs during acute HCV infection (17), 
although their study populations were composed of participants with 
symptomatic jaundice, which occurs during no more than 20% of acute 
HCV infections.    
Circulating miR-885-5p has been less extensively characterized 
than miR-122. Gui et al. reported that serum miR-885-5p levels are 
increased in the setting of hepatocellular carcinoma, cirrhosis, and chronic 
hepatitis B (56). Our finding that miR-885-5p was elevated in acute 
infection is consistent with these previous findings and suggests that 
elevation in plasma miR-885-5p is likely part of a conserved response to 
liver stress. 
To date, only two other publications exist regarding the role of miR-
551b in any biological process (57, 58). Fu et al. describe a down-
regulation of miR-551b in hepatoma cells expressing a mutant of the 
hepatitis B virus HBx protein that induces higher levels of cellular 
proliferation and Xu et al. describe a role for miR-551b in acquired 
apoptosis and chemotherapy resistance in human lung cancer cell-lines. 
Interestingly, we found that this miRNA reduced HCV replication even 
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after adjusting for cellular abundance (Figure 1-9). Further investigation 
into the mechanism of miR-551b is necessary and may reveal a novel 
antiviral response mediated by miR-551b with activity against viruses 
other than HCV.  
Interestingly, both miR-122 (59–62) and miR-885-5p (63–65) have 
been identified as potent tumor suppressors with functional significance in 
cancer progression. In contrast, miR-494, which decreased in plasma 
abundance but increased within hepatocytes during acute HCV infection, 
has been reported to have oncogenic potential in hepatocytes (66) and 
anti-proliferative effects in breast cancer cells (67). As mentioned above, 
miR551b appears to have proliferative and anti-apoptotic properties in 
certain settings. Recent attention has focused on extracellular miRNAs as 
having the potential to regulate recipient cell gene expression (21–29); 
therefore, it is possible that the changes in extracellular miRNAs during 
acute HCV infection could compose part of an innate response to viral 
infection that modulates cellular proliferation and viral replication. Our 
finding that HCV RNA levels were inversely associated with changes in 
extracellular let-7b, a known anti-viral that is induced by interferon, support 
the hypothesis that the circulating miRNA signature may be part of an anti-
viral response. 
There were several limitations to this study.  The large number of 
miRNAs considered increases the risk of type 1 error.  Accordingly, we 
took the conservative approach by correcting for multiple comparisons.  
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More importantly, we confirmed our findings using multiple approaches: i) 
by identifying the same signature in a completely distinct group of 
individuals in the UFO cohort; ii) by finding that miRNA levels of the 
signature were invariant in uninfected IDUs over matching time intervals; 
and iii) by confirming the signature in vitro. We note that differences at 
baseline between the discovery and validation cohorts should have made 
it less likely that we would find the same circulating miRNA signature by 
chance, further supporting the validity of our findings. 
On the other hand, it is possible that some small associations of 
miRNAs with acute HCV infection were missed by a study of this size.  
However, unlike larger cross-sectional studies in which disease 
associations are often confounded by person-to-person variability, we 
studied longitudinal samples in the same person before, during, and after 
acute HCV infection to establish consistent patterns of circulating miRNA 
abundance. Relative to cross sectional studies, this approach markedly 
improved our power by controlling for person-to-person variance.   
Another limitation is that we did not sample liver directly. However, 
it would be unethical to use liver tissue in humans obtained for that 
purpose since liver biopsies are not routinely indicated during acute HCV 
infection and are very rarely performed before HCV infection. Therefore, 
we examined miRNA changes in hepatoma cells infected with HCV in vitro 
and used previously published data on miRNA expression in healthy liver.  
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There are remaining questions about the role of circulating miRNAs 
in acute HCV infection.  Our results suggest that extracellular miRNA 
release is sequence-specific and correlates with the onset and outcome of 
HCV infection.  Given the contribution of the implicated miRNAs in HCV 
replication and the prediction of clinical outcomes during chronic infection, 
these findings also suggest that the pathophysiology of chronic HCV 
infection may be established acutely as part of an innate response to viral 
infection.  Future research is required to understand the mechanism of 
miRNA sorting and the role of plasma miRNAs in HCV infection.  
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CHAPTER 2: A polymorphism in hypervariable 
region 1 confers resistance to broadly neutralizing 
antibodies targeting opposite termini of the 
hepatitis C virus E2 protein. 
Abstract 
Broadly neutralizing monoclonal antibodies (bnAbs) are informative 
for development of vaccines against highly variable viruses including 
hepatitis C virus (HCV), since they target relatively conserved viral 
epitopes that could serve as vaccine antigens.  However, HCV resistance 
to bnAbs is poorly understood. HC33.4 and AR4A are two of the most 
potent bnAbs characterized to date, binding near the amino- and carboxy-
terminus of HCV envelope (E2) protein, respectively.  Given their distinct 
epitopes, it was surprising that these bnAbs clustered together in an 
analysis of neutralization profiles across a panel of natural HCV isolates, 
suggesting that some viral polymorphisms may confer resistance to both 
bnAbs; however, a competing hypothesis requiring mechanistic study was 
that the resistance polymorphisms co-evolved rather than sharing a 
mechanistic basis for resistance.  To investigate this resistance, we 
developed a large, diverse panel of HCV variants and a novel 
computational method using amino acid sequence variation and 
neutralization sensitivity to identify bnAb resistance polymorphisms in E2.  
We identified polymorphisms conferring resistance to each bnAb 
individually, as well as a polymorphism outside of either binding epitope 
that confers resistance to both bnAbs.  
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This diverse viral panel in conjunction with a novel computational pipeline 
allows measurement of neutralizing antibody breadth, and prediction of 
naturally occurring bnAb resistance polymorphisms in E1E2. This analysis 
identified a polymorphism in hypervariable region 1 conferring resistance 
to two potent broadly neutralizing human mAbs targeting opposite termini 
of the E2 protein, and the method is broadly applicable to future studies to 
define mechanisms of HCV resistance to bnAbs. 
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Introduction 
Hepatitis C virus (HCV) infects over 170 million people worldwide 
(3) and kills more people in the United States annually than HIV (68). 
Appalachian regions of the United States saw a >350% increase in the 
number of new HCV infections from 2009-2012 (69) and recent outbreaks 
in the United States have been attributed to the rapid increase in injection 
drug use (70). While direct-acting antiviral (DAA) therapy has 
revolutionized care for patients with HCV, control of the HCV pandemic 
remains challenging due frequent reinfection in high-risk individuals who 
have achieved a sustained virologic response from DAA therapy (71), 
transmission of NS5A inhibitor-resistant HCV variants from individuals 
failing DAA therapy (72), and the high proportion (~50%) of the infected 
individuals in the United States who are unaware asymptomatic carriers 
(73).  
A major barrier to the development of a prophylactic vaccine for 
HCV is eliciting an immune response that is protective against a significant 
proportion of the naturally occurring viral variants (74, 75). Broadly 
neutralizing antibodies (bnAbs) against HCV prevent successful entry of a 
wide variety of naturally occurring HCV isolates. Globally, a majority of 
HCV infections are categorized into 6 genotypes based on genetic 
sequence that differ in their global localization with multiple subtypes 
occurring within some genotypes. Our group has recently reported 
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significant intragenotypic variation in sensitivity to a majority of the bnAbs 
characterized to date using an array of reporter viral particles displaying 
naturally occurring HCV envelopes (HCVpp) (76). Curiously, when the 
abilities of a panel of bnAbs to neutralize an array of 19 HCV genotype 1 
envelopes were compared, distinct relationships between antibodies were 
observed, allowing grouping of all bnAbs into three distinct neutralization 
clusters, and suggesting that common E1E2 determinants of neutralization 
sensitivity are shared between bnAbs within each cluster.  
One neutralization cluster includes the potent bnAbs HC33.4 and AR4A, 
although their described binding epitopes are near opposite termini of the 
E2 protein (Figure 2-1)(77, 78). We hypothesized that shared E1E2 
resistance polymorphisms to these antibodies would explain the 
unexpected correlation between neutralization profiles of HC33.4 and 
AR4A. 
 46 
Materials and Methods 
Source of E1-E2 full-length envelope isolates. Plasma samples 
obtained from HCV infected subjects in the BBAASH cohort [15,16], Irish 
Anti-D cohort (79), and Swan Project (80) were used to construct a library 
of genotype 1 E1E2-expressing lentiviral pseudoparticles using a high-
throughput production and screening approach. 
 
HCV E1E2 expression plasmids. The E1E2 region was PCR amplified 
from cDNA reverse transcribed from viral RNA purified from subject 
plasma and cloned into the expression vector pcDNA3.2/V5/Dest 
(Invitrogen) using Gateway technology in a one-tube BP/LR reaction, as 
previously described (81).  
 
Phylogenetic Analysis. Sanger sequencing of the entire length of the 
cloned E1E2 region was performed in both directions. Amino acid 
sequences from a nucleic acid MUSCLE alignment (82) were used to build 
a phylogenetic tree.  Initial tree(s) for the heuristic search were obtained 
automatically by applying Neighbor-Join and BioNJ algorithms to a matrix 
of pairwise distances estimated using a JTT model, and then selecting the 
topology with superior log likelihood value(83). All trees are drawn to 
scale, with branch lengths measured in the number of substitutions per 
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site, and all positions containing gaps and missing data were eliminated. 
Evolutionary analyses were conducted in MEGA6 (84). 
 
High-throughput HCVpp production and infectivity screening. HCVpp 
were produced from purified cDNA clones by lipofectamine-mediated 
transfection of HCV E1E2 and pNL4-3.Luc.R-E- plasmids into HEK293T 
cells in 96-well plates as previously described(81). Huh 7.5.1 cells were 
exposed to supernatants from 293T cell cultures in order to test for the 
presence of infectious HCVpp, as previously described (81). HCVpp were 
considered infectious if the luciferase activity in Huh 7.5.1 cell lysates was 
greater than 10,000 RLU. Isolates could have been from the same 
infected subject, however, must have differed by at least one amino acid 
from every other clone contained in the library. Envelopes that displayed 
enhanced infection (relative infection >1.2 with either bnAb) were 
discarded not included in the analysis or in the description of library meta-
data.  
 
Subject-adjusted Neutralizing Antibody Prediction of Resistance 
(SNAPR) algorithm. Amino acid alignments built as described in the 
phylogenetic analysis. To account for the uneven distribution of the 
infectious clones per subject, isolates from the library were selected at 
random from each person and added to the initial data set until all subjects 
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were represented by an equal number of isolates. This expanded 
alignment was then divided into groups at each amino acid position in the 
alignment based on amino acid present. Median associated relative 
infection values from each group were assigned and the relative infection 
values from the group with the lowest median relative infection value were 
compared to the relative infection values of all other groups using a Mann-
Whitney U-test. All statistical analyses were performed using R version 
3.1.2. 
 
Site Directed Mutagenesis. The top ten positions were selected for 
further testing. The predicted ancestral clone was tested at each position, 
as was the clone with the highest sensitivity to HC33, the clone with the 
lowest sensitivity, the clone with median sensitivity out of all those 
containing the amino acid most closely associated with high sensitivity, 
and the clone with median sensitivity out of all those containing the amino 
acid associated with low sensitivity. Mutants were created using the 
QuickChange Lightning Multi Site-Directed Mutagenesis Kit (Agilent) and 
≥2-fold coverage by Sanger sequencing was performed to verify that all 
mutants differed from parent clones at only the desired locus. 
 
Infectivity Measurements. Ninety-six-well flat bottom tissue culture 
plates (Falcon) were plated with 8,000 Hep3B cells per well and incubated 
overnight in a humidified CO2 incubator at 37oC. Media was removed from 
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the cells the following day and replaced with 50 µL of HCVpp. The plates 
were placed in a CO2 incubator at 37oC for 5 hours, after which the 
HCVpp were removed and replaced with 100 µL of phenol-free Hep3B 
media. After approximately 72 hours in the CO2 incubator, media was 
removed from the cells and 50 µL of 1x Cell Culture Lysis Reagent 
(Promega) added and left to incubate for >5 minutes then 45 µL from each 
well were then transferred to a white, low-luminescence 96-well plate 
(Berthold) and read in a Berthold Luminometer (Berthold Technologies 
Centro LB960). Each sample was tested in duplicate. A mock 
pseudoparticle (no envelope) was used as a negative control. 
 
Measurements of Neutralization. The same procedure used to measure 
infectivity was employed, but instead of pure pseudoparticle being added 
to the Hep3B cells, 50 µl of a mixture of 10% antibody (original 
concentration 10µg/ml) and 90% pseudoparticle (by volume) that had 
been incubated at 37oC for 1 hour was added. HCVpp were tested in 
duplicate against both the antibody being tested and IgG, the negative 
control. Murine Leukemia Virus (MLV) was used as a positive control.   
 
Calculation of Resistance. The mean fluorescence from the HCVpp 
tested against the antibody was calculated and divided by the mean RLU 
from the same pseudoparticles tested against IgG to determine the 
fraction of infection. The fraction of infection in presence of the antibody 
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was then divided by the fraction of infection in the presence of IgG to 
determine the relative resistance of each mutant. 
 51 
Results 
The expanded library of envelopes contains 117 distinct full-length 
naturally occurring E1E2 sequences. To construct a library of 
envelopes to predict relationships between sequence and neutralization 
sensitivity, we cloned 113 naturally occurring HCV genotype 1 envelopes 
that produced functional HCV pseudoparticles (HCVpp) containing a 
















































































































































Figure 2-1. Construction of an E1E2 HCV envelope panel for neutralizing antibody 
breadth testing and sequence prediction of neutralizing antibody resistance 
polymorphisms. (A) Phylogenetic tree of E1E2 amino acid sequences determined by 
maximum likelihood (log likelihood=8668) shown with the distances drawn to scale. (B) 
Number of different amino acids present at each position in the full E1E2 panel 
alignment. Previously defined HC33.4 and AR4A binding epitopes are indicated (blue and 
pink), as is hypervariable region 1 (HVR1) (gray) and the portion of E2 included in the E2 
core crystal structure determined by Kong et al, (ref) (green)(C) Spearman correlation 
between relative infection of 113 HCVpp in the presence of HC33.4 and AR4A.  Each 
point indicates neutralization of a single HCvpp by HC33.4 on the x-axis and AR4A on 
the y-axis.  
 
The resulting library includes 71 subtype 1a originating and 42 
subtype 1b HCV envelopes (Figure 2-1A). This library contains 97% of 
amino acid polymorphisms present at greater than 5% frequency in a 
reference panel of 643 genotype 1 HCV isolates from GenBank (85) 
resulting in as many as 10 amino acid options in a single locus. The 
largest variety of sampling was observed in parts of the envelope not 
included in crystalized E2 (Figure 2-3). 
 
Neutralization of the expanded panel of HCV envelope by AR4A and 
HC33.4 also displays large variation in bNAb sensitivity. By 
comparing entry efficiency of these envelopes in the presence of a 
HC33.4 or AR4A with entry in the presence of an isotype control, we 
quantified the relative infection of each envelope in the presence of each 
bnAb. AR4A and HC33.4 were associated with a median (IQR, min-max) 
relative infection of 0.17 (0.09-0.25,0.01-1.15) and 0.22 (0.09-0.27,0.003-
1.1) respectively. Interestingly, HC33.4 more potently neutralized subtype 
1a (relative infection median=0.17,IQR=0.06-0.35) than subtype 1b 
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(relative infection median=0.27,IQR=0.17-0.36) envelopes (P=0.002) while 
AR4A displayed no significant difference in subtype neutralization.  
 
Shared sensitivity profiles for AR4A and HC33.4 is also observed in 
the expanded panel of HCV envelopes. 
As was previously reported, the new library also displayed a significant 
correlation in neutralization sensitivity between HC33.4 and AR4A (r=0.44 
p=7x10-7) (Fig 1). Interestingly, this correlation was not as strong as we 
observed in our previous report that was based on just 19 isolates, 
suggesting that the expanded library now contains additional unshared 








































HCV Polyprotein Position (ref=H77)
























































































Figure 2-2. Identification of position-specific sequence variation that significantly 
relates to neutralization sensitivity. (A) Subtype differences in relative infection. (B) At 
each envelope alignment position, isolates were divided into group according to amino 
acid present. Relative infection (infection in the presence of mAb/infection in the 
presence of nonspecific IgG) values from the most sensitive group (as determine by the 
medians) was compared to the relative infection associated with all other amino acid 
choices as a single group. (C) The resulting significance values (after adjustment for 
isolate subject origin) using only subtype 1a clones against HC33.4 and AR4A. 
Previously defined HC33.4 and AR4A binding epitopes are indicated (blue and red), as is 
hypervariable region 1 (HVR1) (gray). 
 
Figure 2-3. SNAPR analysis of all genotype 1 isolates. The significance values (after 
adjustment for isolate subject origin) using all genotype 1 clones against HC33.4 and 
AR4A. Shown epitopes are based on data from previous reports. Previously defined 


























































































region 1 (HVR1) (gray), and the portion of E2 included in the E2 core crystal structure 
determined by Kong et al (86) (green). 
 
Subject-adjusted Neutralizing Antibody Prediction of Resistance-
polymorphisms (SNAPR) and (LASSO): using variation in sequence 
and neutralization sensitivity to predict resistance polymorphisms in 
the HCV envelope. Nearest-neighbor joining alignments were built and at 
each amino acid position all envelopes were divided into groups according 
to the residue occupying that position. The neutralization values at those 
sites were compared and a Wilcoxon-rank sum test was performed 
comparing the neutralization values of all clones carrying the amino acid 
associated with the highest neutralization sensitivity with the neutralization 
values of all of the other clones (Figure 2-2B). Due to the higher degree of 
similarity among isolates originating from the same subject, neutralization 
data from isolates from underrepresented subjects were randomly 
selected for repeating until the number of data points in the library 
representing each individual was identical. Because of the potential for 
subtype differences to dominate findings, grouped genotype (Figure 2-3) 
and subtype 1a only analyses were performed separately. Grouped and 
subtype 1a only p-values spanned approximately 10 and 20 orders of 













Polymorphism SNAPR LASSO 
 
Polymorphism SNAPR LASSO 
X408M 1.82E-19 3.30E-02 
 
X438L 1.68E-14 -4.24E-02 
X403L 1.48E-14 -4.34E-02 
 
X438V NA 3.37E-02 
X629V 1.47E-13 2.79E-02 
 
X403L 1.40E-13 -4.74E-02 
X242M 2.00E-10 -3.76E-02 
 
X242M 1.20E-10 -3.34E-02 
X438L 3.55E-09 -2.94E-02 
 
X255T 9.04E-10 3.39E-02 
X492R 4.74E-09 -2.91E-02 
 
X334V 4.80E-09 3.14E-02 
X445Y 2.17E-08 2.84E-02 
 
X431E 1.41E-08 -3.96E-02 
X396T 5.45E-08 4.04E-02 
 
X444Y 1.65E-08 2.95E-02 
X393G 9.21E-08 -4.42E-02 
 
X501Q 3.25E-07 -2.91E-02 
X496I 1.86E-07 -3.28E-02 
 
X410N 1.34E-06 3.35E-02 
X399L 5.31E-07 4.29E-02 
 
X359M 2.23E-06 2.91E-02 
X641E 1.47E-06 -3.67E-02 
 
X401G 1.16E-03 -3.74E-02 
X401N 2.04E-06 4.05E-02 
 
X396T 1.63E-03 3.13E-02 
X404S 2.77E-06 3.38E-02 
 
X397S 5.46E-03 3.70E-02 
X610N 1.07E-05 -2.91E-02 
 
X397R 5.46E-03 -3.00E-02 
X431E 7.47E-04 -2.80E-02 
 
X384T 1.88E-02 4.01E-02 
X303G 4.08E-03 3.71E-02 
 
X384S NA -3.10E-02 
X388S 1.72E-02 4.27E-02 
 
X387Y 2.88E-02 3.09E-02 
X446K 3.06E-01 3.06E-02 
 
X405Q 4.98E-02 -3.87E-02 
X402L 6.45E-01 2.86E-02 
 
X402L 2.03E-01 4.13E-02 
 
Table 2-1. Agreement between Subject-adjusted (SNAPR) and phylogenetic-
adjusted (LASSO) methods resistance polymorphism predictions based on the 
same data set. The 20 most significant resistance polymorphism predictions by LASSO 
for HC33.4 and AR4A, cross referenced with SNAPR P-values. Predictions that were 
identified in the top 20 both predictions of both algorithms are shown in bold. 
 
Because variation in the distance between any given two clones in 
the library, we also implemented a method that adjusts specifically for 
phylogeny, and not just by subject. The same data set was analyzed using 
this modality. The 20 most significant predictions from LASSO for HC33.4 
and AR4A (Table 2-1) were compared to the top 20 most significant 














































































Figure 2-4. Comparison of relative infection of HCVpp produced using E1E2 clones 
with each amino acid residue at positions predicted to influence bnAb sensitivity. 
Boxplots showing the relative infection values for all isolates grouped by amino acid 




HC33.4 and AR4A resistance polymorphisms are distributed outside 
of described epitopes for each. Both SNAPR and LASSO predicted that 
X403L, X242M, X408M, X438L, X492R, and X629V were determinants of 
neutralization sensitivity for HC33.4 although the described binding 
epitope is between polyprotein positions 410-423. Similarly, X403L, 
X438L, X431E, X244T, X438T, X334V, and X396T were predicted to be 
determinants of neutralization sensitivity to AR4A by both algorithms 
though the described epitope is split between the amino (polyprotein 
positions 200-210) and carboxy (polyprotein positions 650-710) termini of 
E2 (Figure 2-3). 
 
Polyprotein Position 403 is significantly associated with HC33.4 and 
AR4A neutralization efficiency. Given the imperfect correlation in 
neutralization sensitivity between HC33.4 and AR4A, it is not surprising 
that many of loci predicted to be determinants of sensitivity to HC33.4 and 
AR4A are not shared. Interestingly, multiple analytic modalities revealed 
that 403 as a shared determinant of neutralization sensitivity for HC33.4 
and AR4A.  
For HC33.4, a leucine occupation at polyprotein position 403 was 
associated with a median (IQR) 0.042  (0.0048 to 0.13) fraction infection in 
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the unadjusted data and a median (IQR) 0.0064 (0.0047 to 0.064) fraction 
infection in the SNAPR adjusted data. In contrast, phenylalanine was 
associated with a median (IQR) 0.22 (0.097 to 0.36) fraction infection in 
the unadjusted data and a median (IQR) 0.22 (0.10 to 0.38) fraction 
infection in the SNAPR adjusted data (Figure 2-4A). A Wilcoxon rank-sum 
comparison of the HC33.4 fraction infection of isolates containing leucine 
with values of those containing phenylalanine resulted in a P-value of 
9.9x10-4 in the unadjusted data, and a P-value of 1.5e-14 in the subject 
adjusted data. LASSO analysis assigned a coefficient of -0.044 for L403F 
with HC33.4, the strongest coefficient produced (Table 2-1). 
For AR4A, a leucine occupation at polyprotein position 403 was 
associated with a median (IQR) 0.080 (0.050 to 0.18) relative infection in 
the unadjusted data and a median (IQR) 0.067 (0.017 to 0.13) fraction 
infection in the SNAPR adjusted data. In contrast, phenylalanine was 
associated with a median (IQR) 0.20 (0.11 to 0.44) relative infection in the 
unadjusted data and a median (IQR) 0.22 (0.14 to 0.45) fraction infection 
in the SNAPR adjusted data (Figure 2-4B). A Wilcoxon rank-sum 
comparison of the AR4A fraction infection of isolates containing leucine 
with values of those containing phenylalanine resulted in a P-value of 
0.012 in the unadjusted data, and a P-value of 1.4e-13 in the subject-
adjusted data. Analysis with lasso coefficient of -0.043 for L403F with 
AR4A, the second strongest coefficient produced (Table 2-1). 
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Figure 2-5. Fold change in neutralization resistance after site-directed mutagenesis 
at polyprotein position403 in multiple unrelated E1E2 clones. (A) Fold change in 
resistance of HCVpp with two unrelated wild type (WT) E1E2 proteins or HCVpp with the 
same E1E2 proteins after introduction of L403F. (B) Fold change in neutralization of 
HCVpp with two unrelated wild type (WT) E1E2 proteins or HCVpp with the same E1E2 
proteins after introduction of F403L. 
 
Mutations introduced into sensitive and resistant clones validate 403 
as a shared resistance polymorphism. To test the prediction that amino 
acid occupation at position 403 could be a shared determinant of 
sensitivity to HC33.4 and AR4A, we introduced a leucine (the amino acid 
associated with sensitivity) into multiple resistant HCV envelopes bearing 
a phenylalanine (the amino acid associated with resistance) using site-
directed mutagenesis (SDM). SDM of leucine at position 403 to 
phenylalanine (L403F), in the E1E2 background isolates 1a53 and 1a154 
(H77), which differ at 46 amino acids out of the 581 amino acid alignment, 
conferred a 3.0-12.3-fold increase in resistance to HC33.4 (P<0.01 for 
each background). Interestingly, the same mutations conferred 2.5-5.3-


































Conversely, site directed mutagenesis of phenylalanine at position 
403 to leucine (F403L), in the E1E2 backgrounds 1a115 and Bole1a 
(subtype 1a ancestral sequence), which differ at 38 amino acids out of the 
581 amino acid alignment, conferred a 3.0-12.3-fold increase in resistance 
to HC33.4 (P<0.01 for each background). The same mutations also 
conferred 2.5-5.3-fold increase in resistance to AR4A (P<0.01 for each 
background)(Figure 2-5B). 
 
Figure 2-6. Binding of HC33.4 and AR4A is not impacted by SDM at position 403. 
Binding of HC33.4 or AR4A to wildtype (WT) E1E2 proteins or E1E2 with leucine mutated 




























We have developed a high-throughput platform for prediction of 
HCV bnAb resistance polymorphisms and identified an unexpected shared 
resistance polymorphism for two highly potent bnAbs for HCV not 
contained within the described epitopes for either.  
As our ability grows to query larger and larger sets of naturally 
occurring HCV isolates for their sensitivity to broadly neutralizing 
antibodies, so does our understanding of variation in sensitivity—thereby 
addressing a key barrier to developing an effective prophylactic vaccine to 
HCV. In a previous report, we found that antibodies tend to cluster into 
groups with respect to the isolates that they neutralize the most potently. 
Conventional wisdom would predict that these clusters are defined by their 
shared epitopes. The observation that a shared and unshared resistance 
polymorphisms to two broadly neutralizing antibodies that fall into the 
same neutralization cluster are located at positions in neither antibody’s 
described epitope suggests that these clusters are defined by something 
far more complex.  One theory is that HCV varies greatly in its receptor 
dependence (as it has >4 described entry factors) and that these clusters 
are defined by a group of isolates with a specific preference in receptor 
tropism. In this theory, all the antibodies that fall into the cluster interrupt a 
specific entry preference. Interestingly, we profiled the binding affinity of 
SDM envelopes at position 403 and found no difference in binding affinity 
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(Figure 2-6) further suggesting that the mechanism of resistance 
confirmed by this polymorphism and the features that define neutralization 
clusters are more complex than simple antibody-epitope interactions. 
Recent visualization of the E2 protein in complex with a bnAb has 
been informative (86), however, large deletions in E2 to facilitate 
crystallization preclude analysis of many putative antibody/epitope 
interactions. To simulate global diversity, broad neutralization has typically 
been assessed through evaluation of neutralization potency in several 
representative clones per genotype in the context of a replication 
competent genotype 2a HCV genome (77). While HCV E1E2 full-length 
chimeras allow for observation of the extended life-cycle of HCV infection, 
there limited availability means that they encapsulate only a minority of 
intragenotypic variation.  
While we were able to identify an unexpected resistance 
polymorphism to multiple bnAbs, there were limitations to the study design 
and approach.  We only sampled 97% of the naturally occurring 
polymorphisms that exist at a ≥5% threshold in a large set of Genbank 
HCV genotype 1 sequences. When the minimum frequency threshold for 
polymorphism incidence is reduced to ≥1%, the coverage is reduced to 
78%. As has been observed in the emergence of DAA resistance, even 
resistant clones with <1% pretreatment frequency within a single host is 
sufficient for treatment failure (87). More extensive panels are required to 
probe rarely occurring natural polymorphisms in HCV. Though all 
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envelopes were isolated from individuals with ongoing viremia only ~50% 
of the isolates produced functional envelopes in the HCVpp system. This 
may reflect the distribution of functional viruses that circulate in the blood 
of infected patients but likely represents a bias with unknown 
consequence—a limitation existent at a greater frequency in all in vitro 
systems for HCV to date. Due to the lack of robust animal models for HCV 
infection that represent similar inoculum requirements, frequency of 
spontaneous resolution, and viral replication/diversity, it is likely that the 
only validation for broad neutralization and resistance will be in the form of 
vaccine efficacy studies. While these studies are ongoing, we provide 
another line of reasoning that supports vaccination strategies that promote 
the generation of antibody responses spanning more than one 
neutralization cluster. 
In conclusion, we sampled 113 naturally occurring HCV envelopes 
for their sensitivity to two of the most potent broadly neutralizing 
antibodies characterized to date and found significant variation in isolate 
sensitivity and identified a shared resistance polymorphism located 
outside the predicted binding epitope of both antibodies. We have 
previously identified that neutralizing antibodies fall into distinct clusters 
with respect to which isolates they neutralize most potently. Here we have 
presented evidence that one feature of this clustering is far more complex 
than simple epitope recognition. More extensive panels are required to 
 66 
identify more rare but potentially significant resistance polymorphisms for 
broadly neutralizing antibodies. 
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Chapter 3: Identification of novel interferon-induced 
restriction factors for HIV-1 from inter-human 
variation in activated T-cell transcription and virus 
dynamics in vivo. 
Abstract 
The production of type 1 interferons is critical to host inhibition of 
Simian and Human Immunodeficiency viruses (SIV and HIV 
respectively)(88–90).  Though there are hundreds of interferon-stimulated 
genes (ISGs), which of these restrict HIV-1 replication is largely unknown 
(with several notable exceptions(91–95)). To identify ISGs that restrict 
HIV-1 replication, we selected HIV-1 permissive cells (CD38+/HLA-
DR+/CD4+/CD3+ lymphocytes, or activated CD4+ T-Cells) from 19 
humans with untreated HIV-1 infection before and after administration of 
pegylated-interferon alpha 2a (IFN) and studied RNA abundance using 
RNA sequencing (RNAseq).  By comparing the target cell RNA 
abundance induced by IFN by the resultant reduction in plasma HIV-1 
RNA, we identified 13 ISGs that might explain how interferon restricts HIV-
1 replication. Included were recognized (e.g.s, MX2, APOBEC3A) and 
mostly novel HIV-1 (e.g.s, BCL2L14, CMPK2, and LAMP3) candidate HIV-
1 restriction factors. Using principal component analyses to identify ISGs 
that independently restrict HIV-1 replication, we selected CMPK2 and 
BCL2L14 for further study novel candidate restriction factors.  Each of 
these and MX2 (as control) was confirmed (P<0.05) by using RNA 
interference to attenuate the effect of interferon on HIV-1 replication in cell 
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culture.  These studies provide new insights into how type-1 interferons 




Interferons are host defense cytokines that are found in all 
vertebrates (96). Their release coordinates the expression of hundreds of 
cell-autonomous defense genes (interferon-stimulated genes; ISGs) to 
control intracellular pathogens, especially viruses. Interferon-alpha (IFN), 
a quintessential type 1 interferon, has been used to treat chronic virus 
infections, and has activity against HIV-1: HIV-1 infected individuals 
treated with IFN experience a decline in the abundance of plasma viral 
RNA (97) and the number of cells harboring viral genomes (98), 
presumably by inducing ISGs that restrict HIV-1 replication. The 
interferon-induced cytidine deaminase APOBEC3G introduces stop 
codons into retroviral genome intermediates preventing their ability to 
produce infectious progeny (4). These inactivated viruses shape the 
functional diversity of HIV-1 genomes within the latent reservoir, an 
identified barrier to cure (99). Several other HIV-1 restriction factors that 
are ISGs have been described, such as SAMHD1, BST2, and MX2, but 
they do not fully account for the antiviral effects of IFN. Hundreds of ISGs 
are induced upon IFN administration; however, only a select group of them are 
likely to be responsible for restricting HIV-1 replication. We searched for novel 
ISGs that are also HIV-1 restriction factors in infected people who 
received IFN.  
The natural history of HIV-1 infection, which includes declining 
CD4+ T-cell abundance without a decrease in circulating virus, suggests 
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that viral replication is relatively insensitive to changes in the availability of 
uninfected cells. Indeed, established models also suggest that viremia is 
robust to changes in the availability of uninfected cells and much more 
sensitive to changes in the rates of infection and virus production in 
permissive cells Thus, we reasoned that variation in the induction of ISGs 
with restrictive capacity for HIV-1 in infected and otherwise permissive 
cells determines the variation in the decline in HIV-1 viremia in response 
to IFN in vivo.  We sought to identify novel restriction factors for HIV-1 by 
comparing person-to-person differences in HIV-1 restriction and 
transcription dynamics in activated CD4 T-cells from HIV-1 infected 
patients through IFN treatment using a novel analytical approach to 
human cohort RNA sequencing (RNAseq). 
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Materials and Methods 
Modeling the contributions of various features of HIV-1 infection. The 
three differential equations dx/dt = λ-dx-βxv, dy/dt = βxv-ay, and dv/dt = 
ky-uv (λ =production rate of uninfected cells, x=number of uninfected cells, 
d=decay rate of uninfected cells, β=first order rate constant of infection, 
v=plasma viral load, y=number of infected cells, a=decay rate of infected 
cells, and k=first order rate constant of virus production in infected cells) 
were integrated using “integrateODE” function in the ‘mosiac’ package 
version 0.9.2-2 in R (www.r-project.org) version 3.1.2 for 1000 days using 
standard starting values (x=1e6,y=1,v=100000, λ=1e5,d=0.1,a=0.5,B=2e-
7,k=100,u=5) (100–102). The solution values were then used as input into 
another integration but varying either x, β, k, or a by the indicated factor 
and run to simulate an additional 3 weeks (300 days for a) with these new 
imposed values. 
 
Human subjects. The primary outcome was to compare gene expression 
in activated T-cell with HIV RNA changes following administration of IFN 
(ΔHIVIFN): 20 persons with HIV-HCV coinfection were enrolled in a 
prospective study of HIV and HCV viral kinetics pre-antiretroviral therapy 
(ART). Persons with chronic HIV and HCV infections were recruited from 
the Johns Hopkins HIV Clinic, the Baltimore City Sexually Transmitted 
Diseases Clinic, and other area clinics. HIV infection was established by 
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detection of HIV-1 antibodies and an HIV RNA level >400 c/mL; chronic 
HCV infection was determined by detection of HCV antibodies and HCV 
RNA >100,000 IU/mL for >6 months. Subjects had received <24 months of 
ART over their entire lives and none within 6 months. Subjects also were 
excluded if HBsAg was detected in plasma; they were pregnant; there was 
a history of severe depression or any uncontrolled disease; platelet count 
was <50,000/mm3; there was a contraindication to use of raltegravir, 
tenofovir DF, or emtricitabine. Because therapy was judged too urgent to 
wait for study procedures as per current treatment guidelines for HIV and 
HCV, persons at screening whose CD4+ T lymphocyte counts were 
<200/mm3 or who had cirrhosis were excluded. A total of 32 patients were 
screened to identify 20 study subjects. All subjects gave written informed 
consent to the protocol as approved by the Johns Hopkins Institutional 
Review Board. 
Subjects were admitted to the Johns Hopkins Hospital Clinical 
Research Unit. A single 1.5 µg/kg of peginterferon alpha 2b (IFN) was 
administered subcutaneously. Thereafter, blood was collected every 6 
hours and the patient was discharged 24 hours after the IFN dose. The 
patient returned 48 hours, 72 hours, 7 days, and 14 days after the IFN 
dose. At day 14, ART consisting of raltegravir, tenofovir, and emtricitabine 
was given by the Johns Hopkins Research Pharmacy Investigational Drug 
Service. The Johns Hopkins University School of Medicine Institutional 
Review Board approves this study. 
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Laboratory Testing. Unless otherwise indicated, all laboratory testing 
was performed in the clinical laboratory of the Johns Hopkins Hospital. 
Single-nucleotide polymorphisms (SNPs) at position rs12979860, which 
lies upstream of IFNL3, have been strongly associated with HCV RNA 
changes to IFN. To assess IFNL3 status, DNA was extracted from 
peripheral blood mononuclear cells using the QIAamp DNA Blood Mini Kit 
(Qiagen), and SNP genotype at position rs12979860 was performed with 
TaqMan custom SNP genotyping assays (Life Technologies) and using a 
Roche LightCycler 480 Real-Time System (Roche Applied Science, 
Indianapolis, IN).  
 
Viral RNA Testing. To reduce interassay variance, HCV and HIV RNA 
testing for a given subject was done at the same time on plasma 
centrifuged within 30 minutes of collection and stored at −20°C for up to 
25 hours and then at −80°C until testing. HCV RNA testing was done 
using the RealTime HCV Amplification Reagent Kit Abbot). To provide 
information in “real time,” such as for screening into the study, additional 
HCV RNA tests were done by the commercial laboratory of the Johns 
Hopkins Hospital using the Roche Cobas AmpliPrep/Cobas TaqMan HCV 
Test, v. 1.0. Although both were reported in international units, analyses 
were primarily done on results from one or the other laboratory. HIV RNA 
testing was done using the RealTime HIV Assay (Abbott). HCV genotype 
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was determined in the Johns Hopkins Hospital clinical laboratory by direct 
sequencing of the Core-E1 regions of the HCV genome. CD4+ T-
lymphocyte count was measured by flow cytometry of whole blood that 
was delivered to the Johns Hopkins Hospital clinical laboratory. 
 
Isolation of activated CD4 T-cells. Peripheral blood mononuclear cells 
(PBMCs) were separated from whole blood and frozen as previously 
described (103). Freshly thawed cells were washed and incubated with 
CD3-FITC (Biolegend, San Diego, CA), CD4-PECy7 (Biolegend), CD8-
APC (BD Biosciences), HLA-DR-PE (Biolegend), and CD38-BV421 
(Biolegend) 40 minutes at 4ºC per the manufacturer’s recommendation. 
Immediately before sorting, plasma membrane compromised cells were 
labeled with propidium iodide (Sigma). Flourescence-activated cell sorting 
(FACS) was performed on a MoFlo Legacy Sorter (Beckman-Coulter) at 
the Johns Hopkins School of Public Health Flow Cytometery Core Facility. 
The population of interest was sorted directly into ≥4 volumes of Quick-
RNA™ MicroPrep lysis buffer (Zymo Research) per the manufacturer’s 
recommendation. Sorting was stopped when the number of sorted cells 
reached 125,000 cells although many samples did not reach this number. 
Flow-cytometry analysis on two randomly selected post-sort samples 
revealed >95% purity. Sorted samples were vortexed, incubated for 10 




Activated T-Cell RNA isolation. Isolation was performed using the 
Quick-RNA™ MicroPrep kit (Zymo Research, Irvine, CA) according the 
manufacturer’s protocol without the on-column DNAase treatment. The 
eluate was treated with DNAse-I (Qiagen, Germantown, MD) according to 
the manufacturer’s protocol then purified and concentrated using the RNA 
Clean-up and Concentrator kit (Zymo Research, Irvine, CA) according the 
manufacturer. The high-sensitivity assay for RNA or DNA was performed 
on RNA isolations and cDNA libraries respectively using a 2100 
Biolanalyzer (Agilent). 
 
Library preparation and sequencing. Complementary DNA (cDNA) 
libraries were produced using the Ovation® Single-cell RNAseq kit 
(NuGEN) according to the manufacturer’s specifications. Briefly, reverse 
transcription was carried out using a random hexamer to oligodT ratio of 
50:1 and unique barcodes for each individual’s samples were ligated to 
~250bp enzymatically fragmented molecules. All samples were linearly 
amplified using 19 cycles of PCR using primer annealing sites contained 
within the adapters. All sequencing was performed on a HiSeq2500 
(Illumina) at the Johns Hopkins Genetics Research Core Facility. Each 
individual’s samples were pooled three to each lane (one other sample 
from a third time point was included from each individual for an unrelated 
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project) in an equimolar fashion and read in rapid-run mode to produce 
100bp paired-end reads. 
 
Sequence Mapping. To avoid resampling of fragments due to PCR 
duplication, identical sequences were removed from data as is standard 
practice. Reads were assembled with RSEM (104) using hg19 as the 
reference human genome. Transcript variant analysis was performed 
using all annotated UCSC isoforms as of 7/15/2014.  
 
Differential Expression Calculation. Differential expression of genes 
and isoforms was calculated using EBseq, an empirical Bayes hierarchical 
model for expression analysis of RNAseq data (105).  
 
Statistical Analyses. Comparison values, including post-correction fold-
change, post-correction probability of differential expression (PPDE), and 
post-correction probability of equal expression (PPEE) values, were 
further analyzed in using ‘stats' in R version 3.1.2. Measurements for 
which neither the PPDE or PPEE was ≥0.95 were discarded. In the 
determination of significance of the gene’s change across the cohort, all 
fold-change calculations with PPEE ≥ 0.95 were set to 0. If there were 
remaining measurements for a gene in >10 of the individuals, a two-sided 
one-sample T-test was performed on log2 transformed fold-change values. 
The resulting P-values were adjusted for multiple comparisons using the 
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Benajami-Hochberg method (38). Genes with adjusted P-values ≤0.05 
were considered ISGs. Spearman rank-correlations were performed 
between fold-changes between the observed ISGs and viral load decline 
with fold-changes with PPEE ≥ 0.95 retained as their original values.  
Pairwise correlation plots were constructed using ‘corrplot’ version 0.73. 
K-means clustering was performed using ‘cluster’ version 1.15.3. Wilcoxon 
rank-sum tests were performed on untransformed data in discovery 
analyses unless indicated otherwise. Two-sample unpaired one-way t-
tests were performed in cell-culture studies as these experiments were 
performed to validate observations previously made in vivo. 
 
In vitro IFN treatments. Six cell lines THP-1, MT4, MOLT4, A3.01, PM1, 
and Jurkat cells (NIH AIDS Reagent Bank) were treated with 1,000 U/mL 
IFN for 0,6,12, and 24 hours and RNA was isolated using the QuickRNA 
microprep kit (Zymo Research). Reverse transcription was performed 
using SuperScript III (Invitrogen) according to the manufacturer’s protocol 
using oligo-dT primers only. Quantitative PCR was performed using 
LightCycler SybrGreen master mix (BioRad) according to the 
manufacturer and run on the LightCycler 480 (BioRad) according to the 
manufacturer’s protocol. Fold-changes are shown in reference to 
untreated samples and normalized to the geometric mean of Ct values 
from RPL13, RPL37, and β-actin (Integrated DNA technologies, assay IDs 
Hs.PT.58.47294843, Hs.PT.58.1213197, and Hs.PT.56a.40703009.g 
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respectively) measured using the LightCycler 480 Probes master mix 
(BioRad). 
 
Virus Preparation. The full-length HIV-IIIB, pNL4.3 delta nef GFP or 
pNL4.3 delta env (mock) plasmids were transfected into 293T cells and 
supernatants were spinnoculated onto PM1 cells (NIH AIDS Reagent 
Bank) for 2 hours at 1,200g. Cells were then incubated at 37ºC for 10 
days. Supernatants were passed through 0.22 µm filter and virus was 
pelleted through a 20% sucrose layer for 2 hours at 150,000g. Pellets 
were resuspended in RPMI containing 10% FBS and stored at -80ºC. 
Virus concentration was determined using the 96-well format Alliance HIV-
1 P24 Antigen Elisa kit (Perkin-Elmer, Waltham, MA) according to the 
manufacturer’s protocol. 
 
Testing cell lines for their IFN-mediated restriction potential for HIV-
1. The indicated five cell lines (NIH AIDS Reagent Bank) were centrifuge 
inoculated with varying amounts of HIV-IIIB. For each inoculum 
concentration, 200,000 cells were centrifuge inoculated with 50µL of RPMI 
containing 10% FBS at 1,200g for 2 hours. Cells were allowed to rest for 
24 hours at 37ºC and then each inoculum was split into two wells, one that 
received no treatment while the other received 1,000 U/mL IFN. Both wells 
were incubated for an additional 72 hours at 37ºC before supernatants 
were collected and p24 measurements were performed. 
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In vitro RNAi, infection, IFN treatment, and measurement of HIV 
production. MT4 cells (NIH AIDS Reagent Bank) were transfected with 
SMARTpool siGENOME siRNAs (Dharmacon) negative controls or 
siRNAs at 100nM against the indicated gene of interest using the Amaxa 
Cell Line Nucleofector V kit (Lonza) according to the manufacturer’s 
protocol. Cells were rested in recovery media (20% FBS) at 37ºC for 24 
hours and 200,000 cells were centrifuge-innoculated with purified 
replication-competent HIV-IIIB (10pg p24) in 50uL of 10%FBS RPMI at 
1,200g for 2 hours. After washing twice with media, cells were rested for 
24 hours at 37ºC and split into two wells: one containing 1,000 Units 
IFN/mL and one containing an equal volume of the same 10% FBS RPMI 
used to resuspend the IFN (untreated). After 48 hours of IFN treatment, 
supernatants were removed, diluted 1:1,000 in DMEM containing 10% 
FBS. One hundred microliters of this dilution was transferred to 10,000 
TZM-bl cells (NIH AIDS Reagent Bank) in 100uL DMEM containing 10% 
FBS and 20µg/mL diethylaminoethanol and incubated at 37ºC for 48 
hours. Cells were washed with PBS and assayed for luciferase activity 
using the Luciferase assay kit (Promega). Fraction infection was 
calculated by dividing the luciferase reading from the TZM-bl cells 
exposed to the IFN-treated supernatants by the luciferase from the TZM-bl 
cells exposed to the untreated supernatants.
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Results 
Figure 3-1. HIV-1 viremia is more sensitive to changes in the rate of infection and 
the rate of virus production than changes in the availability of uninfected target 
cells. Infections were simulated using three standard differential equations dx/dt = λ-dx-
βxv, dy/dt = βxv-ay, and dv/dt = ky-uv (λ =production rate of uninfected cells, x=number 
of uninfected cells, d=decay rate of uninfected cells, β=first order rate constant of 
infection, v=plasma viral load, y=number of infected cells, a=decay rate of infected cells, 
and k=first order rate constant of virus production in infected cells) using the starting 
values (x=1e6,y=1,v=100000, λ=1e5,d=0.1,a=0.5,B=2e-7,k=100,u=5). Resulting values 
were then used as input into the same equations separately varying the indicated 
variable by the indicated factor and run for 21 days. 
 
Modeling plasma HIV-1 RNA kinetics after IFN. We adapted standard 
mathematical models of HIV-1 kinetics after antiviral treatment to consider 
an array of ISGs as putative antivirals, accounting for how IFN might affect 
HIV-1 viremia (100, 102, 106). Because IFN administration is known to 
cause a reduction in CD4+ T-cell abundance in HIV-1 infected 
































































ISG induction or by decreasing the availability of target cells. We 
hypothesized that ISGs could either affect the rate of infection of 
susceptible cells (β) or the rate of virus production in infected cells (k) 
(Figure 3-1).  Modeling revealed that HIV-1 kinetics after IFN 
administration was more consistent with ISG induction affecting β or k, 
rather than a change in the total number of target cells.  
Table 3-1. Participant Characteristics. 






Male, n (%) 
Race 





















HCV genotype,* n (%)  
    1a 15 (79) 
    1b 1 (5.3) 
    2b 1 (5.3) 
    3a 2 (10.5) 
IFNL3 (rs12979860) genotype, n (%)  
    C/C 1 (5.3) 
    C/T 11 (57.9) 







Figure 3-2. In vivo IFN responsiveness and activated CD4 T-cell transcriptome 
library preparation. (A) Boxplots with overlaid values of log10 changes in HIV and HCV 
RNA from baseline are shown with lines connecting values from each subject over the 
indicated time-points. Lines indicate longitudinal measurements from the same individual. 
(B) Scatterplot and boxplots comparing the percent decline in viremia from baseline for 
HIV and HCV at each subject’s corresponding nadir virus measurement. (C) Flow 
cytometery data and sorting algorithm for isolation of activated CD4 T-cells from total 
PBMCs at baseline (Pre, blue) and after 24 hours after injection with IFN (IFN, red). (D) 
Boxplots with overlaid points showing the percent of CD4 T-cells bearing the activation 
markers HLA-DR and CD38 with lines connecting participants across the two measured 
timepoints. (E) Sample bioanalyzer tracing of RNA, overview of library preparation, and 
sample bioanalyzer tracing of prepared cDNA library. Fluorescence units, FU; RNA or 
































































































































Figure 3-3. Activation status changes in CD8 T-cells reveal that IFN activated both 
CD4 and CD8 T-cells. (A) Flow cytometery profiling of activated CD8 T-cells from total 
PBMCs at baseline (Pre, blue) and after 24 hours after injection with IFN (IFN, red). (B) 
Boxplots with overlaid points showing the percent of CD8 T-cells bearing the activation 
markers HLA-DR and CD38 with lines connecting participants across the two measured 
timepoints. 
 
Person-to-person variability in HIV-1 virus kinetics. Administration of a 
single weight-based injection of IFN to 19 untreated HIV-1 infected 
persons resulted in a cohort-wide median (range) 0.85 (0.24 to 2.14) 
log10(decline in HIV RNA copies/mL) at one week (P=0.003)  (Figure 2A).  
Participants were co-infected with HCV, and HCV viral kinetics were 
performed in parallel over the same intervals (13). Strikingly, HIV-1 and 
HCV viral kinetics did not correspond within the same people (Figure 2B), 
suggesting that the ISGs that restrict each virus are distinct.  
 
RNA sequencing from activated CD4+ T cells before and after IFN. 







































































24 hours after IFN. Activated CD4+ and CD8+ T cells, defined by co-
expression of CD38 and HLA-DR, were separately quantified and sorted 
before and after IFN (Figure 3-2C). Compared to pre-IFN, the proportion 
of CD4+/CD38+/HLA-DR+ and CD8+/CD38+/HLA-DR+ T cells increased 
by a median (IQR) 5.4 (-1.6 to 6.9; p=0.02) and 19.1 (14.2 to 22.5; 
P=0.0001), respectively, after IFN (Figure 3-2D and Figure 3-3) 
suggesting that IFN impacts global T-cell activation. We focused on 
activated CD4+ T cells, rather than total or resting CD4+ T-cells (108–
110), pre- and post-IFN to avoid confounding due to their varying 
proportions. Thus activated CD4 T-cells were sorted using fluorescence-
activated cell-sorting (FACS) from all subjects immediately before and 24 
hours after IFN administration. A median (range) of 8.21e4 (1.66e4 to 
1.25e5) cells were sorted from which a median (range) of 36.61 (4.86-
69.59) nanograms of RNA was recovered with a median (range) RNA 
integrity number (RIN) of 9.4 (8.2-9.9). Complimentary DNAs (cDNA) were 
enzymatically fragmented to approximately 250bp and barcoded adapters 
were ligated followed by 19 cycles of linear amplification. Paired-end RNA 
sequencing (RNAseq) was performed (Figure 3-2E) and a median (range) 
of 87e6 (41e6 to 180e6) 100bp sequences were recovered from each 
sample. Duplicate sequences (presumably due to PCR) were removed 
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Figure 3-4. An integrated algorithm for de novo characterization of ISGs in 
activated CD4 T-cells from HIV-1 humans receiving IFN. (A) Histogram showing the 
distribution of PPDE and PPEE for all genes in which a determination could be made 
over the two sampled time-points. Meta-data from a merged data set for all individuals is 
shown. (B) Histogram showing the distribution of the number of genes with the indicated 
number of individuals detecting that gene with PPDE or PPEE≥0.95. Volcano plot 
comparing cohort-wide median post-correction fold-change values (with values 
corresponding to PPEE ≥0.95 set to 0) and p-values for the 9,631 genes with high-
confidence quantitation in at least 50% of the cohort. (D) Boxplots with overlaid points 
showing the individual fold-changes for the 99 genes that significantly changed with IFN 
across the cohort after adjustment for multiple comparisons with no fold-change 
adjustment imposed for PPEE values ≥0.95. 
 
Defining an empirical set of IFN-regulated genes in activated CD4+ T 
cells from cohort RNAseq data. Since we did not know which genes 
would be induced by IFN in activated CD4+ T cells, we first determined a 
set of ISGs in activated CD4+ T cell that were consistently induced in the 
cohort. An empirical Bayes hierarchical clustering model (‘EBseq’) was 
implemented to determine the posterior probability of differential vs. equal 
expression (PPDE and PPEE respectively) and post-correction fold-
change for each gene after IFN treatment in each individual (Figure 3-
4A). In total, 21,930 genes were equally or differentially expressed with a 
posterior probability ≥0.95 in at least one individual; 9,631 were equally or 
differentially expressed with a posterior probability ≥0.95 in ≥11 members 
of the cohort, which was the pre-determined threshold for further study 
(Figure 3-4B). The resulting log2 fold-changes for all individuals (with all 
fold-changes associated with PPEE ≥0.95 set to 0) were tested and 
significance was adjusted for each gene tested (Figure 3-4C). This 
yielded a de novo set of 99 genes that were bona fide ISGs in the 
activated CD4+ T-cells from the 19 people (Figure 3-4D). The list of ISGs 
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included multiple known HIV-1 restriction factors such as MX2 and BST2 
(tetherin), several ISGs with previously described activity against other 
viruses (RSAD2 [Viperin], DDX58 [RIG-I], and IFITM3), and genes that 
have not been previously described as having antiviral roles (including but 
not limited to BCL2L14 [BCL-G], CMPK2, and LAMP3). 
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Figure 3-5. Relating ISG induction with viral RNA decline. (A) Scatter plot comparing 
P-values of Spearman correlations of each ISG’s fold-change with plasma HIV-1 RNA 
decline at one week (y-axis) and plasma HCV RNA decline at one-week nadir (x-axis). 
(B) Individual scatterplots of 10 genes that significantly related to HIV and not HCV viral 
load decline after adjustment for multiple comparisons (scatterplots of MX1, ISG15, and 
IFIT3 are shown in Supplemental Figure). (C) Pairwise correlation plots of fold-changes 
for the genes shown in (B). (D) K-means clustering of principal component analysis 
grouping all points into 5 clusters. The same color scheme used to demark clusters in (D) 
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6,985,000 6,995,000 7,005,000 7,015,000 7,025,000 7,035,000 7,045,000
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An algorithm for identifying ISGs that are putative HIV-1 restriction 
factors. As expected, persons-to-person variability in ISG expression was 
substantial for some genes (Figure 3-4D).  We developed an algorithm 
that ranked ISGs as putative HIV-1 restriction factors by comparing the 
magnitude of increase of each ISG (retaining EBseq post-correction fold-
changes when PPEE≥0.95) with the magnitude of plasma HIV-1 RNA 
decline across the cohort. The algorithm revealed 13 genes whose 
upregulation in activated CD4+ T cells were closely correlated with plasma 
HIV-1 RNA decline. To validate against false detection, we performed the 
same algorithm using HCV kinetics in the same people, and as expected 
found no significantly correlated ISGs.  As expected, no gene-induction 
events in activated CD4 T-cells related to HCV RNA decline significantly 
after adjustment for multiple comparisons, although RSAD2, which related 
to HIV-1 RNA decline did relate to HCV RNA decline with no adjustment 
(P=0.04) (Figure 3-5A). The 13 putative HIV-1 restriction ISGs included 
MX2 and IFI6, two genes that are known to restrict HIV-1 in vitro (8, 91). In 
addition, several genes were identified for which no evaluation of antiviral 
activity has been performed, including BCL2L14, CMPK2, LAMP3 (Figure 
3-5B, Figure 3-6).  
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Figure 3-6. Scatterplots of additional genes that significantly related to HIV-1 
restriction in vivo. Scatterplots labeled with the corresponding Spearman rank 
correlation estimate comparing the post-correction fold-changes of the indicated gene 
with plasma HIV-1 RNA decline at one-week. 
 
We next asked whether induction of these 13 putative restriction 
factors for HIV-1 were induced by IFN in clusters to test whether their 
relative effect on HIV-1 could parsed independently of each other.  
Fortuitously, pairwise-wise correlation analysis of post-correction fold-
change values revealed a hierarchy in the relatedness of gene induction 
(Figure 3-5C). We characterized this hierarchy by performing k-means 
clustering on principal component analysis of the fold-change values and 
revealed five distinct clusters of genes with BCL2L14, APOBEC3A, and 
ISG15 each in their own cluster and the rest of the genes contained in two 
additional clusters (Figure 3-5D). Interestingly, although RSAD2 and 
CMPK2 are directly adjacent to each other on chromosome 2 (Figure 3-
5E), they segregated into two distinct clusters with other members 
distributed across different chromosomes, suggesting differential 





































































































































































Figure 3-7. Multiple MX2 isoforms are induced by IFN and relate to viral restriction. 
(A) Relative genomic positions of MX2 isoform exons. The sole Refseq annotated 
transcript is shown in dark blue and the non-Refseq UCSC variants are shown in light 
blue. Arrow-studded lines indicate 5’ to 3’ directionality of transcripts and connectivity 
between exons (filled bars) and increased girth of bars indicates coding regions. Unfilled 
bars indicate retained introns. (B) Sashimi plots showing the mapped read density 
[range] within regions of MX2 immediately before (Pre, blue), and 24 hours after the 
administration of IFN (IFN, red).  Curved lines are labeled with the number of reads 
spanning the indicated exon-exon junction. (C) Modified boxplots with points overlaid of 
post-correction fold-changes in each isoform with IFN treatment for each individual in 
which the measurement was possible. * P<0.01, ** P≤0.0001. (D) Scatterplots with 
Spearman rank-correlation values showing the relationship between the post-correction 
fold-change values for each gene and virus RNA decline. 
 
Specific ISG isoforms are associated with HIV-1 restriction. 
Differential splicing of transcripts is evident in their sequence and thus 
RNAseq data can be used to examine and quantitate unique splice 
variants within a sample. We subsetted genes by their transcriptional 
variants for MX2, CMPK2, and BCL-G to test the hypothesis that individual 
isoforms were responsible for HIV-1 restriction (LAMP3 has only one 
annotated variant). We examined 5 distinct transcript variants of MX2 
(Figure 3-7A) for their induction by IFN and their relationship with viral 
restriction (Figure 3-7B-C). Four out of the five (3 coding and 1 non-
coding) variants were significantly induced by IFN (P<0.05 for all). Only 
one of the three coding variants (uc002yzf.1), also known as the full-length 
MX2, was associated with viral restriction (P=0.02) (Figure 3-7C). In 
addition, the non-coding variant of MX2, which contains the first exon and 
a partially-spliced retained intron (uc002yzf.1), was highly expressed and 
associated with both to viral restriction (P=0.023) (Figure 3-S3C) and full-
length MX2 expression (P=3.4x10-7), although their splicing is mutually 
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Figure 3-8. CMPK2 isoform analysis (A) Relative genomic positions of all detected 
UCSC annotated CMPK2 isoform exons. Detected variants that are Refseq annotated 
are shown in dark blue and non-Refseq UCSC annotated variants are shown in light blue. 
Arrow-studded lines indicate 5’ to 3’ directionality of transcripts and connectivity between 
exons (filled bars). Increased girth of bars indicates coding regions. (B) Sashimi plots 
showing the mapped read density [range] within regions of CMPK2 immediately before 
(Pre, blue), and 24 hours after the administration of IFN (IFN, red).  Curved lines are 
labeled with the number of reads spanning the indicated exon-exon junction. (C) Modified 
boxplots with points overlaid of post-correction fold-changes in each isoform with IFN 
treatment for each individual in which the measurement was possible. * P<0.01, ** 
P≤0.0001. (D) Scatterplots with Spearman rank-correlation values showing the 
relationship between the post-correction fold-change values for each gene and virus RNA 
decline.  
 
 We performed the same analysis for CMPK2, parsing out 
upregulation of each of five detected isoforms (3 coding and 2 noncoding) 
(Figure 3-8A) after IFN (P<0.05 for all)(Figure 3-8B). All isoforms were 
induced after IFN.  However, similar to MX2, only one coding variant 
(uc002qyo.4) was associated with a decline in plasma HIV-1 RNA level 
after IFN (P=0.006)(Figure 3-8C). 
 
Table 3-2. Quantitative PCR primer sequences and amplicon location by exon.  
Gene Exons Spanned* Forward Primer Reverse Primer
MX2 E1 to E2 TGATTTCTCCATCCTGAACGTG CATGTGCTGTCTCCCTGTC
LAMP3 E2 to E3 ATGTTGAAGTATCTCCGAGGTG GTCAAGACTGGAATTTATCAGGTTC
CMPK2 uc002qyo.4 E7b** AATTTGGGACTGAGGGAGATG CTACACTGGCATGCTGATGA
CMPK2 uc010ewv.4 E6a to E6b** CCCACAGCAGCTACCATTAT CAGTTCTACACCACTGCCTTTA
CMPK2 uc010yis.2 E3 to E4 AATCTGCCAAATCTCCTGTGA CCA AGATTC CAGTCC CAC AA
CMPK2 uc031rno.1 E1 to E2 CGCTCTTAACTGCTCCACAA GAGAGGGCAATTCCAAGAAGA
CMPK2 uc002qyn.2 E2 to E3 AGGTGGAGAGAAGGATGGTATAA AAATGTCCTACCAGCGGATG
BCL2L14 uc001rac.3 E1 to E2 AATATCCTTACTGCCACCTGAC GGGATTTCTTCCAGGTCACA
BCL2L14 uc001rae.3 E4 to E5 GCCAAAATTGTTGAGCTGCT GCCATCAAACCATCCTGTG
*If no isoform specified, then Refseq exon annotation was used.  
**Refer to Figure 3-8 for exon numbering.
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Figure 3-9. In vitro validation of CMPK2 and BCL2L14 as IFN-induced restriction 
factors for HIV-1. (A) Real-time qPCR data showing individual isoforms for CMPK2 and 
BCL2L14 as well LAMP3 and MX2 regulation in response to IFN in the 6 indicated cell 
lines at 0, 6, 12, and 24 hours. (B) IFN-mediated inhibition of HIV-1 in the indicated 5 cell 
lines known to support HIV replication. (C) Experimental scheme for measuring IFN-
mediated inhibition of HIV-1 in cells in which CMPK2 and BCL-G have been down-
modulated by RNAi. (D) Barplots showing inhibition measurements with error bars 
indicating standard error over the mean from 3 replicate transfections. * indicates P<0.05. 
 
IFN inducibility and capacity for HIV-1 restriction of CMPK2, 
BCL2L14, and LAMP3. We tested whether IFN induced the putative HIV-
1 restriction factors BCL2L14, LAMP3, and CMPK2 by treating multiple 
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intracellular mRNA levels of each gene using RT/qPCR with qPCR primer 
sets spanning unique exons or exon/exon junctions to distinguish the 
individual isoforms (Figure 3-9A). All three putative restriction factors 
were increased upon IFN treatment in most of the cell lines that were 
tested, although to different degrees. Notably, some isoforms of each 
gene were more robustly induced than others: e.g., BCL-GL isoform 
uc001rac.3 exhibited <10-fold IFN-induction in 5/6 cell lines, whereas 
BCL-GS isoform uc001rae.3 exhibited >10-fold induction in 5/6 cell lines.  
CMPK2 isoform uc002qyo.4 was induced in 5/6 cell lines, although not in 
MT4 cells (Figure 3-9A).  
We next established which cell line(s) supported robust HIV-1 
replication, and in which did IFN demonstrate the most antiviral activity.  
Six cell lines were inoculated with infectious HIV-1 at titrated 
concentrations to establish replication capacity of the virus in the cells 
(Figure 3-9B).  Separate well were treated with IFN to inhibit viral 
replication. MT4 cells appeared to support the most robust HIV-1 
replication and were also the most potent inhibitors of HIV-1 replication in 
response to IFN. 
RNAi was used to determine if CMPK2 and BCL2L14 expression 
contributed to IFN-mediated restriction of HIV-1 in vitro. We transfected 
MT4 cells with siRNAs directed against CMPK2, BCL2L14, and MX2 as a 
positive control and then treated cells with IFN (Figure 3-9C). IFN resulted 
in a 92.6% inhibition of virus production in cells transfected with negative 
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control siRNAs (Figure 3-9C). In cells where siRNAs against MX2, our 
positive control were introduced, IFN resulted in a 72.3% inhibition of virus 
production, a significantly less amount than the negative control siRNA 
(P=0.015). When siRNAs against CMPK2 were introduced into these cells, 
IFN resulted in a 72.1% inhibition of virus production, a significantly less 
amount than the negative control siRNA (P=0.019) (Figure 3-9C). IFN 
treatment of cells in which siRNAs against BCL2L14 had been introduced 
resulted in an 86.2% inhibition of virus production, a significantly less 





By sequencing mRNAs in the principal cells in which HIV-1 
replicates, we have identified IFN-induced HIV-1 restriction factors that 
directly contribute to the effect of IFN on HIV-1 among infected people 
with uncontrolled viremia. Our findings underscore the remarkable 
diversity of the IFN transcriptional program that is in place to defend 
against scores of intracellular pathogens: of the 99 ISGs that we identified 
in activated CD4+ T cells, only a fraction were relevant for HIV-1.  The 
complexity of IFN signaling and ISG regulation is also evident, and was 
seen from the level of the individual to the level of each unique gene 
isoform.  Understanding how our novel panel of ISGs restricts HIV-1 
replication may illuminate vulnerabilities in the life cycle of an otherwise 
efficient pathogen that can be exploited as therapeutic targets. 
There have been several genome-wide explorations of HIV-1 
restriction factors, and these have yielded a plethora of insights about 
HIV-1 replication (111, 112). However previous reports have either hinged 
on the use of cell lines for discovery, or have utilized cell types that are not 
the natural target of HIV-1 infection. In addition, by using an open-ended 
sequencing approach, we have developed a rigorously-defined panel of 
ISGs in activated CD4+ T cells, expanding the list of ISGs that have been 
previously described as relevant in HIV-1 (113).   
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CMPK2 has been annotated as an ISG before, but not as an 
antiviral effector.  Its genomic location on Chromosome 2 is nestled 
between RSAD2 and the newly described NRIR, an interferon-induced 
long non-coding RNA (linc-RNA) that is a negative regulator of IFN 
responses.  Hence, CMPK2 sits in a transcriptionally active hotspot for 
IFN regulation. Our data collectively support that CMPK2, and not RSAD2 
or NRIR, restricts HIV-1 replication in activated CD4 T-cells.  CMPK2 
catalyzes the phosphorylation of dUMP to dUDP, an intermediate step in 
the overall conversion of dUMP to dUTP. It is possible that increasing 
intracellular stores of dUTP may contribute to the lethal uracylation of 
retroviral genomes that has been described elsewhere (114). All CMPK2 
coding isoforms contain the active site of the translated protein, and all 
were induced by IFN, so it is not clear why only the uc002.qyo.4 isoform 
was associated with HIV-1 restriction in vivo. The CMPK2-uc002.qyo.4 
isoform differs from the other isoforms only in an additional 41 amino acids 
at the N-terminus, and in that it has a unique 3’UTR. These differences 
suggest that the CMPK2- uc002.qyo.4 isoform may possess modified 
activity conferred by the additional domain and/or that the stability of the 
transcript is improved by this alternate 3’ UTR. 
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Figure 3-10. The impact of infected cell decay rate on HIV-1 virmeia. As in Figure 1, 
infections were simulated using three differential equations dx/dt = λ-dx-βxv, dy/dt = βxv-
ay, and dv/dt = ky-uv (λ =production rate of uninfected cells, x=number of uninfected 
cells, d=decay rate of uninfected cells, β=first order rate constant of infection, v=plasma 
viral load, y=number of infected cells, a=decay rate of infected cells, and k=first order rate 
constant of virus production in infected cells) using the starting values 
(x=1e6,y=1,v=100000, λ=1e5,d=0.1,a=0.5,B=2e-7,k=100,u=5). Resulting values were 
then used as input into the same equations varying a by the indicated variable by the 
indicated factor and run for 300 days. 
 
The function of BCLG remains poorly understood. There is 
controversy as to whether BCL-G is involved in apoptosis (115, 116). The 
BCLG nomenclature derives from its BH2 and BH3 domains, although the 
extent of its similarity to canonical BH-containing proteins such as BCL2 is 
unknown. Although IFN is known to reduce CD4+ T cell counts, this is 
believed to occur through bone-marrow production suppression and not 
increased apoptosis of terminally differentiated cells. Without a massive 
shift to apoptosis in IFN exposed cells, it is tempting to theorize that if 
BCL2L14 increases the tendency for apoptosis, it does so selectively (i.e. 















































modeling suggests that an increased decay rate of infected cells could 
enduringly suppressing viremia to below 1 copy/liter when the decay rate 
increases by ≥8-fold (Figure 3-10).  While knockdown of BCL2L14 
isoforms significantly limited IFN-mediated HIV-1 restriction, it was to a 
lower extent than CMPK2 or MX2. This may have been due to the 
observation that MT4 cells, the cell type in which the RNAi experiment 
was performed, was the most potent inducer of BCL2L14 and significant 
residual induction through IFN treatment still occurred. More potent 
suppression or oblation of the locus is needed to confirm this hypothesis. 
We encountered several challenges in this investigation.  Biases in 
reverse transcription and the library preparation may have favored the 
most abundant transcripts that were then targeted for sequencing, omitting 
less abundant but still relevant transcripts.  This may have resulted in 
patchy quantification of some transcripts across the cohort.  To account 
for this possibility, we pre-specified that we would only analyze transcripts 
that were detectable in ≥11/19 individuals to ensure that only consistently 
detected genes were considered.   A second challenge was in selecting 
CD4+ T cell markers that corresponded well with HIV-1 infected or HIV-1 
susceptible cells.  We used CD38 and HLA-DR, which are well 
established for identifying activated CD4+ T cells.  However, It is possible 
that other markers would have more specifically identified HIV-1 
susceptible cells.  Focusing on only HIV-1 infected cells, however, would 
have omitted the effects of IFN on preventing infection of new cells, which 
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translates mathematically to which ISGs impact β, the first order rate 
constant of infection (Figure 3-1). An important point is that we did not 
have sufficient power to do a complete isoform analysis on all of the 
21,930 unique genes that were sequenced.  However, we were able to 
analyze the isoforms of individual genes of interest after employing the 
computational algorithm to identify putative ISG HIV-1 restriction factors. 
Further research is needed to understand how the functional activity of 
these isoforms differ, especially with regard to CMPK2 and MX2.  
Furthermore, while our in vitro RNAi experiments against CMPK2 
demonstrated that it plays a role in IFN-mediated HIV-1 restriction, this 
was evident in the MT4 cell line, which did not demonstrate a substantial 
increase in CMPK2 expression upon IFN stimulation.  These results 
suggest that CMPK2 catalysis may be rate-limiting for IFN-mediated 




































































Figure 3-11. Multiple isoforms for BCL2L14 are induced by IFN. (A) Relative genomic 
positions of BCL2L14 isoform exons. Refseq annotated transcripts are shown in dark 
blue and the non-Refseq UCSC variants are shown in light blue. Arrow-studded lines 
indicate 5’ to 3’ directionality of transcripts and connectivity between exons (filled bars) 
and increased girth of bars indicates coding regions. Unfilled bars indicate retained 
introns. (B) Sashimi plots showing the mapped read density [range] within regions of 
BCL2L14 immediately before (Pre, blue), and 24 hours after the administration of IFN 
(IFN, red).  Curved lines are labeled with the number of reads spanning the indicated 
exon-exon junction. (C) Modified boxplots with points overlaid of post-correction fold-
changes in each isoform with IFN treatment for each individual in which the measurement 
was possible. * P<0.01, ** P≤0.0001. (D) Scatterplots with Spearman rank-correlation 
values showing the relationship between the post-correction fold-change values for each 
gene and virus RNA decline. Missing points are from individuals in which the isoform 
could not be identified. 
 
The likelihood that specific exons and junctions within a gene will 
have sufficient coverage for quantitation depends on many features 
including (but not limited to) exon size, location (terminal sequence is less 
likely to be captured), expression relative to all other genes, and number 
of sequences acquired for each sample. There were three detected UCSC 
isoforms of BCL2L14 defined by two differential splice sites in our 
samples. One of these sites is between the 4th and 5th exon, however, it 
only distinguishes uc001rad.3 from uc001rac.3 or uc001rae.3. Detection 
of the splice site that distinguishes uc001rac.3 from uc001rae.3 (short 
non-coding exon 1) was sufficiently low to preclude quantitation for 11/19 
individuals (Figure 3-11). With these data we were able to determine that 
all isoforms were induced by IFN treatment, however, we were unable to 
establish a significant rank-correlation relationship with any particular 
isoform. Due to the priceless nature of RNAs acquired from these 
specimens, high likelihood of low expression of these isoforms in pre-
treated samples, and importance of quantitating many reference genes for 
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accurate normalization, we elected not to employ qPCR to determine for 
changes of individual isoforms.   
We provide evidence for two novel interferon-induced HIV-1 
restriction factors. HIV-1 restriction factors provide insights into the 
ongoing battle between pathogen and host, and may provide novel 
therapeutic targets for HIV-1 control. Unlike many other identified host-
restriction factors for HIV-1, the genes we identified are highly variable in 
their induction from host-to-host providing an inconsistent landscape of 
restriction for HIV-1 to realize fitness advantage. Whether or not this is a 
protective mechanism for host species whose generation time and 




This thesis presents three novel methods for sampling natural HCV 
and HIV infections to describe novel features of the molecular biology of 
infection.  
By comparing plasma miRNA levels in a well-characterized cohort 
before, during, and after acute HCV infection in chapter one, we identified 
a consistent and specific extracellular miRNA signature of acute infection 
that validated in two separate methods; in another cohort and in a tissue 
culture model of infection.  Contrary to predictions made by conventional 
wisdom, circulating miRNA abundance during acute infection was not 
simply the result of cellular necrosis but indeed a nonrandom process of 
retention and release that tracked with the onset and control of virus 
infection.  This suggests that extracellular miRNA release is sequence-
specific and is a result of the onset and outcome of HCV infection.  Given 
the contribution of miRNAs in HCV replication, their prediction of clinical 
outcomes during chronic infection, and their potential to regulate networks 
of gene expression, these findings also suggest that the pathophysiology 
of chronic HCV infection may be established acutely as part of an innate 
response to viral infection.  
In chapter two, we developed a high-throughput platform for 
prediction of HCV bnAb resistance polymorphisms and identified an 
unexpected shared resistance polymorphism for two highly-potent bnAbs 
for HCV not contained within the described epitopes for either. By 
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sampling 113 naturally occurring HCV envelopes for their sensitivity to two 
of the most potent broadly neutralizing antibodies characterized to date, 
we found significant variation in isolate sensitivity and identified a shared 
resistance polymorphism located outside the predicted contact residues of 
both antibodies. Previous research from our lab has identified that 
neutralizing antibodies fall into distinct clusters with respect to which 
isolates they neutralize most potently. We presented evidence the unifying 
features of clustering are far more complex than simple epitope 
recognition.  
In chapter three, we sequenced mRNAs in the principal cells in 
which HIV-1 replicates and subsequently identified IFN-induced HIV-1 
restriction factors that contribute to the effect of IFN on HIV-1 among 
infected people with uncontrolled viremia. These IFN-induced restriction 
factors for HIV-1 provide insights into the ongoing battle between 
pathogen and host to replicate and limit the repercussions of infection. 
Since host factors are relatively static in their sequence, their proteins and 
pathways may provide novel therapeutic targets for controlling HIV-1 
infection. Unlike many other identified host-restriction factors for HIV-1, the 
genes we identified are highly variable in their induction from host-to-host 
providing an inconsistent landscape of restriction for HIV-1 to realize 
fitness advantage heightening the possibility that viral proteins that target 
their destruction may not exist.  
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 The findings in chapters one and three not only highlight the 
importance of characterizing relationships in humans, but that significant 
and profound person-to-person differences are evident even in early and 
short sampling intervals. The findings in chapter two suggest viral evasion 
from neutralization is far more complex than sequence changes in binding 
epitopes and perhaps a far more complex process involving significant 
structural and receptor tropism changes through mutation in other parts of 
the envelope. These findings too underscore the importance of studying 
natural infections in humans, and particularly the person-to-person 
differences that may be a previously unappreciated host species-specific 
defense mechanism against pathogens.  
In conclusion, careful and limited sampling of humans with natural 
viral infections can provide insights for which no model can provide 
surrogacy. In particular, genetic variation between hosts within a species 
and viral infections that they harbor are particularly useful in dissecting the 
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